Synthesis of the Monomeric Counterpart of Marinomycin A and B

Frederic Ballaschk,^a Kathrin Bensberg,^a Benedikt Crone^{b,c}, Stefan F. Kirsch^{a,e} and Helge Menz^{b,d}

^a Organic Chemistry, University of Wuppertal, Wuppertal, Germany

- ^b Department Chemie, Technische Universität München, Garching, Germany
- ^c BASF SE, Ludwigshafen am Rhein (Germany)

^d Pharmpur GmbH, Königsbrunn (Germany)


^esfkirsch@uni-wuppertal.de

1. General remarks	4
2. Experimental procedures	5
2.1 Condition screening for the acetonide deprotection of 23	5
2.2 Fragment synthesis	5
(E)-3-(tributylstannyl)prop-2-en-1-ol ⁴ (17)	5
(<i>E</i>)-3-(tributylstannyl)acrylaldehyde ⁵ (18)	5
(<i>E</i>)-but-1-en-3-yn-1-yltributylstannane ⁷ (19)	7
(E)-trimethyl(4-(tributylstannyl)but-3-en-1-yn-1-yl)silane (6)	7
(Z)-2,2,3,3,10,10,11,11-octamethyl-4,9-dioxa-3,10-disiladodec-6-ene ⁹ (13a)	7
2-((<i>tert</i> -butyldimethylsilyl)oxy)acetaldehyde ¹⁰ (20)	3
(<i>E</i>)-4-((<i>tert</i> -butyldimethylsilyl)oxy)-2-methylbut-2-enal ¹⁰ (22)	3
(<i>S</i>)- <i>tert</i> -butyl((4-(2,2-dimethyl-6-vinyl-1,3-dioxan-4-ylidene)-3-methylbut-2-en-1- yl)oxy)dimethylsilane ^{2,3} (23)	9
(S,E)-9-((tert-butyldimethylsilyl)oxy)-3-hydroxy-7-methylnona-1,7-dien-5-one ¹¹ (24)	9
(3S,5S,E)-9-((tert-butyldimethylsilyl)oxy)-7-methylnona-1,7-diene-3,5-diol (26)10	C
(<i>9S</i> , <i>11S</i> , <i>E</i>)-9-((<i>tert</i> -butyldimethylsilyl)oxy)-2,2,3,3,7,13,13,14,14-nonamethyl-11-vinyl-4,12-dioxa- 3,13-disilapentadec-6-ene (27)1	
<i>tert</i> -butyl(((<i>E</i>)-4-((<i>4S</i> ,6 <i>S</i>)-2,2-dimethyl-6-vinyl-1,3-dioxan-4-yl)-3-methylbut-2-en-1- yl)oxy)dimethylsilane (28)	1
(4S, 6S)-6- $((E)$ -4- $((tert$ -butyldimethylsilyl)oxy)-2-methylbut-2-en-1-yl)-2,2-dimethyl-1,3-dioxane-4-carbaldehyde ¹² (30)	
((<i>4</i> S, <i>6S</i>)-6-((<i>E</i>)-4-((<i>tert</i> -butyldimethylsilyl)oxy)-2-methylbut-2-en-1-yl)-2,2-dimethyl-1,3-dioxan-4- yl)methanol (31)	3
<i>tert</i> -butyl(((<i>E</i>)-4-((<i>4S</i> ,6 <i>S</i>)-6-(((4-methoxybenzyl)oxy)methyl)-2,2-dimethyl-1,3-dioxan-4-yl)-3- methylbut-2-en-1-yl)oxy)dimethylsilane (32)	3
(9S,11S,E)-9-((<i>tert</i> -butyldimethylsilyl)oxy)-11-(((4-methoxybenzyl)oxy)methyl)- 2,2,3,3,7,13,13,14,14-nonamethyl-4,12-dioxa-3,13-disilapentadec-6-ene (33)	4
(2S,4S,E)-2,4,8-tris((tert-butyldimethylsilyl)oxy)-6-methyloct-6-en-1-ol (34)	5
(2S,4S,E)-2,4,8-tris((<i>tert</i> -butyldimethylsilyl)oxy)-6-methyloct-6-enal (7)	5

methyl (<i>R</i>)-2-((<i>tert</i> -butyldimethylsilyl)oxy)propanoate ¹³ (35)	. 16
(<i>R</i>)-2-((<i>tert</i> -butyldimethylsilyl)oxy)propanal ¹³ (36)	. 16
(R)-tert-butyl((1-(2,2-dimethyl-6-vinyl-1,3-dioxan-4-ylidene)propan-2-yl)oxy)dimethylsilane ^{2,3} (3	
(2R,6R)-2-((<i>tert</i> -butyldimethylsilyl)oxy)-6-hydroxyoct-7-en-4-one ¹¹ (38)	
(3R,5R,7R)-7-((<i>tert</i> -butyldimethylsilyl)oxy)-5-hydroxyoct-1-en-3-yl acetate (39)	. 18
(3R,5R,7R)-7-((<i>tert</i> -butyldimethylsilyl)oxy)oct-1-ene-3,5-diol (40)	. 18
<i>tert</i> -butyl(((<i>R</i>)-1-((<i>4R</i> , <i>6R</i>)-2-(4-methoxyphenyl)-6-vinyl-1,3-dioxan-4-yl)propan-2- yl)oxy)dimethylsilane (41)	. 19
(3R,5R,7R)-7-((tert-butyldimethylsilyl)oxy)-5-((4-methoxybenzyl)oxy)oct-1-en-3-ol (42)	. 20
(<i>5R</i> , <i>7</i> S, <i>9R</i>)-7-((4-methoxybenzyl)oxy)-2,2,3,3,5,11,11,12,12-nonamethyl-9-vinyl-4,10-dioxa-3,1 disilatridecane (43)	
(3S,5S,7R)-3,7-bis((tert-butyldimethylsilyl)oxy)-5-((4-methoxybenzyl)oxy)octan-1-ol (44)	. 21
5-(((3R,5S,7R)-3,7-bis((<i>tert</i> -butyldimethylsilyl)oxy)-5-((4-methoxybenzyl)oxy)octyl)thio)-1-pheny 1H-tetrazole (45)	
5-(((<i>3R</i> ,5S,7R)-3,7-bis((<i>tert</i> -butyldimethylsilyl)oxy)-5-((4-methoxybenzyl)oxy)octyl)sulfonyl)-1- phenyl-1 <i>H</i> -tetrazole (8)	. 23
5-hydroxy-2,2-diphenyl- <i>4H</i> -benzo[<i>d</i>][1,3]dioxin-4-one ¹⁴ (16)	. 23
4-oxo-2,2-diphenyl-4H-benzo[d][1,3]dioxin-5-yl acetate (9)	. 24
2.3 Fragment assembly	. 25
(6E,9S,11S,12E,15S,17S,19R)-9,11,15-tris((tert-butyldimethylsilyl)oxy)-17-((4-methoxybenzyl)oxy)-2,2,3,3,7,19,21,21,22,22-decamethyl-4,20-dioxa-3,21-disilatricosa-6,12-diene (46)	. 25
(<i>5R</i> , <i>7S</i> , <i>9S</i> , <i>11E</i> , <i>13S</i> , <i>15S</i> , <i>17E</i>)-9,13,15-tris((<i>tert</i> -butyldimethylsilyl)oxy)-2,2,3,3,5,17,21,21,22,22 decamethyl-4,20-dioxa-3,21-disilatricosa-11,17-dien-7-ol (47)	
(<i>5R</i> , <i>7</i> S, <i>9</i> S, <i>11E</i> , <i>13</i> S, <i>15</i> S, <i>17E</i>)-9,13,15-tris((<i>tert</i> -butyldimethylsilyl)oxy)-2,2,3,3,5,17,21,21,22,22 decamethyl-4,20-dioxa-3,21-disilatricosa-11,17-dien-7-yl 2-acetoxy-6-hydroxybenzoate ¹⁴ (49)	
(<i>5R</i> , <i>7</i> S, <i>9S</i> , <i>11E</i> , <i>13S</i> , <i>15S</i> , <i>17E</i>)-9,13,15-tris((<i>tert</i> -butyldimethylsilyl)oxy)-2,2,3,3,5,17,21,21,22,22 decamethyl-4,20-dioxa-3,21-disilatricosa-11,17-dien-7-yl 2-acetoxy-6- (((trifluoromethyl)sulfonyl)oxy)benzoate (49a)	
(<i>5R</i> , <i>7S</i> , <i>9S</i> , <i>11E</i> , <i>13S</i> , <i>15S</i> , <i>17E</i>)-9, 13, 15-tris((<i>tert</i> -butyldimethylsilyl)oxy)-2, 2, 3, 3, 5, 17, 21, 21, 22, 22 decamethyl-4, 20-dioxa-3, 21-disilatricosa-11, 17-dien-7-yl 2-(methoxymethoxy)-6-	2-
(((trifluoromethyl)sulfonyl)oxy)benzoate (50)	
(<i>5R</i> , <i>7S</i> , <i>9S</i> , <i>13S</i> , <i>15S</i> , <i>E</i>)-9,13-bis((<i>tert</i> -butyldimethylsilyl)oxy)-15-((<i>E</i>)-4-hydroxy-2-methylbut-2-ei 1-yl)-2,2,3,3,5,17,17,18,18-nonamethyl-4,16-dioxa-3,17-disilanonadec-11-en-7-yl 2- (methoxymethoxy)-6-(((trifluoromethyl)sulfonyl)oxy)benzoate ¹⁵ (50a)	
(<i>5R</i> , <i>7S</i> , <i>9S</i> , <i>13S</i> , <i>15S</i> , <i>E</i>)-9,13-bis((<i>tert</i> -butyldimethylsilyl)oxy)-2,2,3,3,5,17,17,18,18-nonamethyl- ((<i>E</i>)-2-methyl-4-oxobut-2-en-1-yl)-4,16-dioxa-3,17-disilanonadec-11-en-7-yl 2-(methoxymethox 6-(((trifluoromethyl)sulfonyl)oxy)benzoate (50b)	(y)-
(<i>5R</i> , <i>7S</i> , <i>9S</i> , <i>13S</i> , <i>15S</i> , <i>E</i>)-9,13-bis((<i>tert</i> -butyldimethylsilyl)oxy)-2,2,3,3,5,17,17,18,18-nonamethyl- ((<i>E</i>)-2-methylpent-2-en-4-yn-1-yl)-4,16-dioxa-3,17-disilanonadec-11-en-7-yl 2-(methoxymethox 6-(((trifluoromethyl)sulfonyl)oxy)benzoate (51)	(y)-
(<i>5R</i> , <i>7S</i> , <i>9S</i> , <i>13S</i> , <i>15S</i> , <i>E</i>)-9,13-bis((<i>tert</i> -butyldimethylsilyl)oxy)-2,2,3,3,5,17,17,18,18-nonamethyl- ((<i>2E</i> , <i>4E</i> , <i>6E</i>)-2-methyl-9-(trimethylsilyl)nona-2,4,6-trien-8-yn-1-yl)-4,16-dioxa-3,17-disilanonaded 11-en-7-yl 2-(methoxymethoxy)-6-(((trifluoromethyl)sulfonyl)oxy)benzoate ^{16,17} (5)	C-
3. References	. 34
4. Spectra	. 35

1. General remarks

The commercially available reagents and solvents were used as purchased. TLC was conducted with precoated aluminum sheets (silica gel 60 F₂₅₄) and visualized by exposure to UV light (254 nm) or stained with ceric ammonium molybdate (CAM) or basic potassium permanganate (KMnO₄), and subsequent heating. Flash column chromatography was performed on silica gel (40-60 µm), the eluent used is reported in the respective experiments. Abbreviations of solvents and chemicals are as followed: CH: cyclohexane, EA: ethyl acetate, tetrahydrofuran, DCM: dichloromethane, MeOH: methanol, THF: DMF: N,Ndimethylformamide. IR spectra were measured using ATR-technique in the range of 400-4000 cm⁻¹. ¹H NMR spectra were recorded with 600 MHz or 400 MHz instruments from *Bruker*, ¹³C NMR spectra at 151 MHz or 101 MHz, ¹⁹F NMR spectra at 376 MHz. Chemical shifts are reported in ppm relative to the solvent signal, coupling constants J in Hz. Multiplicities were defined by standard abbreviations. High-resolution mass spectra (HRMS) were obtained using ESI ionization (positive) on a Bruker micrOTOF. Optical rotation of unknown chiral substances were measured using a Krüss Optronic at 584 nm wavelength. The temperature during measurements was kept at 20 °C with a defined concentration (g/100mL) in the described solvent.



Both enantiomers of the polyketide building block **10** and **11** used in this work were synthesized analogously to the previously published synthesis by Streiber *et al.*¹ and Kirsch *et al.*^{2,3}

2. Experimental procedures

2.1 Condition screening for the acetonide deprotection of 23

entry	acid	solvent	temp.	time	yield
1	Amberlyst 15	MeOH/THF	70 °C	18 h	[a]
2	BCl₃	DCM	RT	20 min	[a]
3	FeCl ₃ /SiO ₂	CHCl₃	RT	1 h	[b]
4	CeCl ₃ .7H ₂ O,(COOH) ₂	MeCN	RT	2 min	48%
5	CeCl ₃ .7H ₂ O,(COOH) ₂	MeCN	0 °C	10 min	60%
6	CeCl ₃ .7H ₂ O,(COOH) ₂	MeCN	-15 °C	20 min	57%
7	CeCl _{3,} (COOH) ₂	THF ^[c]	-78 °C	16 h	63%

Table 1. Condition screening for the acetonide deprotection of 23.

[a] = decomposition; [b] = mixture of compounds; [c] = addition of water (2 equiv.).

2.2 Fragment synthesis

(*E*)-3-(tributylstannyl)prop-2-en-1-ol⁴ (**17**)


Bu₃Sn OH

 $Pd_2(dba)_3$ (41 mg, 43 µmol, 0.25 mol%) was placed in dry dichloromethane (40 mL, 0.43M) in a flamedried flask. Tricyclohexylphosphine (0.49 mL, 0.35 mmol, 20 wt% in toluene, 2 mol%) was added and the reaction was stirred at 0 °C for 15 min. Propargyl alcohol (**12**) (1.0 mL, 17 mmol, 1 equiv.) and tributyltin hydride (5.3 mL, 20 mmol, 1.15 equiv.) were then added and the mixture was stirred at 0 °C for an additional three hours. The solvent was removed under reduced pressure and the remaining residue was purified by column chromatography (CH:EA 95:5). The product **17** (3.4 g, 9.9 mmol, 57%) was obtained as a colorless oil.

TLC: R_f = 0.10 (CH:EA 95:5) [KMnO₄]; ¹**H NMR** (600 MHz, CDCl₃): δ [ppm] = 6.24 – 6.12 (m, 2H), 4.17 (t, *J* = 4.5 Hz, 2H), 1.54 – 1.46 (m, 6H), 1.42 – 1.39 (m, 1H), 1.34 – 1.29 (m, 6H), 0.92 – 0.87 (m, 15H); ¹³**C NMR** (101 MHz, CDCl₃): δ [ppm] = 147.2, 128.5, 66.6, 29.2, 27.4, 13.8, 9.6.

The spectroscopic data were identical to those reported in the literature.⁴

(E)-3-(tributylstannyl)acrylaldehyde⁵ (18)




Allyl alcohol **17** (3.40 g, 9.79 mmol, 1 equiv.) was placed in dry acetone (122 mL, 0.08M) and manganese(IV) oxide (18.9 g, 195 mmol, 20 equiv.) was added. The reaction was stirred at room temperature for 18 hours before filtering over Celite[®]. It was washed with acetone and the filtrate was

concentrated under reduced pressure. Purification of the residue by column chromatography (CH:EA 97:3) afforded the aldehyde **18** (3.27 g, 9.48 mmol, 97%) as a faint yellow oil.

TLC: $R_f = 0.50$ (CH:EA 95:5) [UV, KMnO₄]; ¹H NMR (400 MHz, CDCl₃): δ [ppm] = 9.41 (d, J = 7.5 Hz, 1H), 7.79 (d, J = 19.2 Hz, 1H), 6.63 (dd, J = 19.2, 7.5 Hz, 1H), 1.57 – 1.46 (m, 6H), 1.36 – 1.27 (m, 6H), 1.06 – 0.96 (m, 6H), 0.90 (t, J = 7.3 Hz, 9H); ¹³C NMR (101 MHz, CDCl₃): δ [ppm] = 193.8, 163.3, 147.8, 29.1, 27.4, 13.8, 10.0.

The spectroscopic data were identical to those reported in the literature.⁶

(*E*)-but-1-en-3-yn-1-yltributylstannane⁷ (**19**)




Trimethylsilyldiazomethane (2.67 mL, 5.35 mmol, 2 μ in diethyl ether, 1.5 equiv.) was placed in dry THF (9.10 mL) and cooled to -78 °C. *n*-Butyllithium (1.93 mL, 4.81 mmol, 2.5 μ in hexane, 1.35 equiv.) was added and the reaction was stirred at -78 °C for 30 min. Aldehyde **18** (1.23 g, 3.56 mmol, 1 equiv.) dissolved in THF (4.6 mL) was slowly added and then the reaction was stirred for 60 minutes at -78 °C before warming to 0 °C and stirring for another 30 minutes. The reaction was stopped by the addition of sat. NH₄Cl solution_(aq) and transferred to a separatory funnel. Extraction of the aqueous phase was carried out with diethyl ether (3x) and the combined organic phases were dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. Purification of the residue by column chromatography (PE) afforded the terminal alkyne **19** (715 mg, 2.10 mmol, 59%) as a colorless oil.

TLC: $R_f = 0.58$ (CH) [UV, KMnO₄]; ¹**H NMR** (600 MHz, CDCl₃): δ [ppm] = 6.99 (d, J = 19.9 Hz, 1H), 5.99 - 5.89 (m, 1H), 2.89 (d, J = 2.0 Hz, 1H), 1.59 - 1.42 (m, 6H), 1.31 (h, J = 7.3 Hz, 6H), 0.99 - 0.83 (m, 15H); ¹³**C NMR** (151 MHz, CDCl₃): δ [ppm] = 149.6, 124.7, 84.1, 75.6, 29.1, 27.4, 13.8, 9.8.

The spectroscopic data were identical to those reported in the literature.⁷

(E)-trimethyl(4-(tributylstannyl)but-3-en-1-yn-1-yl)silane (6)




The terminal alkyne **19** (200 mg, 586 µmol, 1 equiv.) was placed in dry THF (5.9 mL, 0.1 μ) and cooled to -78 °C. To this mixture was added *n*-butyllithium (281 µL, 703 µmol, 2.5 μ in hexane, 1.2 equiv.) and the reaction was stirred for one hour at -78 °C. TMS chloride (89.9 µL, 703 µmol, 1.2 equiv.) was then added and the reaction was stirred for another hour at -78 °C before warming up to room temperature and stirring for another 16 hours. The reaction was stopped by the addition of sat. NH₄Cl solution_(aq) and extracted with ethyl acetate (3x). The combined organic phases were dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. Purification of the residue by column chromatography (CH) afforded product **6** (236 mg, 571 µmol, 97%) as a colorless oil.

TLC: R_f = 0.60 (CH) [UV, KMnO₄]; ¹**H NMR** (400 MHz, CDCl₃): δ [ppm] = 6.94 (d, *J* = 19.9 Hz, 1H), 6.00 (d, *J* = 19.9 Hz, 1H), 1.56 - 1.43 (m, 6H), 1.35 - 1.25 (m, 6H), 0.96 - 0.85 (m, 15H), 0.19 (s, 9H); ¹³**C NMR** (101 MHz, CDCl₃): δ [ppm] =148.7, 125.9, 105.5, 92.5, 29.2, 27.4, 13.8, 9.8, 0.1.

The spectroscopic data were identical to those reported in the literature.8

(Z)-2,2,3,3,10,10,11,11-octamethyl-4,9-dioxa-3,10-disiladodec-6-ene⁹ (**13a**)



(*Z*)-But-2-ene-1,4-diol (**13**) (4.28 mL, 50 mmol, 1 equiv.) was placed in dry DMF (100 mL, 0.5M). Imidazole (16.3 g, 240 mmol, 4.8 equiv.) was added and the mixture cooled 0 °C before TBS chloride (18.8 g, 125 mmol, 2.5 equiv.) was added and the reaction was stirred for 16 h at room temperature. Sat. NaHCO₃ solution_(aq) and ethyl acetate were added, the phases were separated, and the aqueous phase was extracted with ethyl acetate (2x). The combined organic phases were washed with sat. NaCl solution_(aq), dried over sodium sulfate, filtered, and the solvent was removed under reduced pressure. Purification of the residue by column chromatography (CH:EA 99:1) afforded product **13a** (15.8 g, 49.9 mmol, quant.) as a colorless oil.

TLC: R_f = 0.24 (CH:EA 98:2) [KMnO₄]; ¹**H NMR** (400 MHz, CDCl₃): δ [ppm] = 5.55 (t, *J* = 3.7 Hz, 2H), 4.23 (d, *J* = 3.7 Hz, 4H), 0.90 (s, 18H), 0.07 (s, 12H); ¹³**C NMR** (101 MHz, CDCl₃): δ [ppm] = 130.4, 59.8, 26.1, 18.5, -5.0.

The spectroscopic data were identical to those reported in the literature.9

2-((*tert*-butyldimethylsilyl)oxy)acetaldehyde¹⁰ (20)


TBSO

Ozone was passed through a solution of internal alkene **13a** (3.95 g, 12.5 mmol, 1 equiv.) in dichloromethane (74 mL, 0.17m) at -78 °C. After about 20 minutes, a blue coloration of the solution occurred, whereupon oxygen was passed through the reaction mixture until the blue coloration faded. Triphenylphosphine (3.83 g, 14.6 mmol, 1.17 equiv.) was added and the mixture was allowed to warm to room temperature. Stirring was continued at this temperature for 90 minutes before most of the solvent was removed under reduced pressure. The remaining residue was purified by distillation *in vacuo* furnishing aldehyde **20** (3.52 g, 20.2 mmol, 81%) as a colorless liquid.

Bp: 79 °C (40 mbar); ¹**H NMR** (400 MHz, CDCl₃): δ [ppm] = 9.70 (t, *J* = 0.8 Hz, 1H), 4.21 (d, *J* = 0.9 Hz, 2H), 0.93 (s, 9H), 0.11 (s, 6H).

The spectroscopic data were identical to those reported in the literature.¹⁰

(E)-4-((tert-butyldimethylsilyl)oxy)-2-methylbut-2-enal¹⁰ (22)




Aldehyde **20** (1.74 g, 10 mmol, 1 equiv.) was dissolved in dry benzene (50 mL, 0.2м) followed by addition of 2-(triphenylphosphoranylidene)propanal (**21**) (3.90 g, 12.0 mmol, 1.2 equiv.). The reaction was stirred at room temperature for 60 h before water was added. The mixture was extracted with diethyl ether (3x) and the combined organic phases were washed with sat. NaCl solution_(aq), dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The remaining residue was purified by column chromatography (CH:EA 95:5) to give product **22** (2.01 g, 9.38 mmol, 94%) as a faint yellow oil.

TLC: $R_f = 0.41$ (CH:EA 90:10) [UV, KMnO₄]; **¹H NMR** (600 MHz, CDCl₃): δ [ppm] = 9.42 (s, 1H), 6.52 (td, J = 5.3, 1.2 Hz, 1H), 4.52 – 4.48 (m, 2H), 1.73 (s, 3H), 0.92 (s, 9H), 0.10 (s, 6H); ¹³**C NMR** (101 MHz, CDCl₃): δ [ppm] = 194.7, 153.2, 137.9, 60.6, 26.0, 18.4, 9.5, -5.1.

The spectroscopic data were identical to those reported in the literature.¹⁰

(S)-tert-butyl((4-(2,2-dimethyl-6-vinyl-1,3-dioxan-4-ylidene)-3-methylbut-2-en-1-


yl)oxy)dimethylsilane^{2,3} (23)



Diisopropylamine (2.22 mL, 15.9 mmol, 1.15 equiv.) was placed in dry THF (53 mL) and cooled to -78 °C. *n*-Butyllithium (6.34 mL, 15.9 mmol, 2.5M in hexane, 1.15 equiv.) was added and cooling was removed for 15 min. Cooling was resumed to -78 °C and the (*S*)-polyketide building block **10** (4.72 g, 13.8 mmol, 1 equiv.), dissolved in dry THF (21 mL), was added. This caused the solution to turn deep red. After one hour, aldehyde **22** (3.84 mg, 17.9 mmol, 1.3 equiv.), dissolved in dry THF (32 mL), was added and warmed to room temperature within 90 minutes. The solution became cloudy and orange in the process. Finally, potassium *tert*-butoxide (1.95 g, 16.5 mmol, 1.2 equiv.) was added and stirred for another 60 minutes at room temperature. The solution turned dark orange to brown. The reaction was stopped by adding sat. NH₄Cl solution_(aq) and extracted with dichloromethane (3x). The combined organic phase was washed with sat. NaCl solution_(aq), dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. Purification of the crude product by column chromatography (CH:EA 95:5) afforded product **23** (3.88 g, 11.5 mmol, 83%, *E/Z* 50:50) as a yellow oil.

TLC: R_f = 0.54 (CH:EA 90:10) [UV, KMnO₄]; **¹H NMR** (400 MHz, CDCl₃): δ [ppm] = 5.93 – 5.76 (m, 1H), 5.59 – 5.09 (m, 4H), 4.48 – 4.33 (m, 1H), 4.28 (t, J = 5.9 Hz, 2H), 2.85 – 2.07 (m, 2H), 1.91 – 1.73 (m, 3H), 1.55 – 1.47 (m, 6H), 0.92 (d, J = 1.8 Hz, 9H), 0.09 (s, 6H); ¹³C NMR (101 MHz, CDCl₃): δ [ppm] = 147.6, 146.3, 138.2, 138.2, 132.6, 131.3, 128.6, 128.4, 116.3, 115.9, 114.0, 101.4, 101.2, 70.7, 69.9, 60.4, 60.3, 35.8, 32.0, 29.2, 29.1, 26.2, 26.1, 22.6, 22.1, 18.5, 17.7, 16.3, -4.9, -4.9; **IR** (ATR): $\tilde{\nu}$ [cm⁻¹] = 2991, 2929, 2894, 2856, 1656, 1381, 1255, 1104, 832, 773; **HRMS** (ESI): [m/z] 361.2169 (calc'd for C₁₉H₃₄NaO₃Si: 361.2171 [M+Na]⁺).

(*S*,*E*)-9-((*tert*-butyldimethylsilyl)oxy)-3-hydroxy-7-methylnona-1,7-dien-5-one¹¹ (**24**)




Cerium(III) chloride heptahydrate was dried *in vacuo* at 140 °C for two hours to obtain dry cerium(III) chloride before starting the reaction. Acetonide **23** (674 mg, 1.99 mmol, 1 equiv.) was placed in dry THF (10 mL, 0.2M) and cooled to -78 °C. Cerium(III) chloride (981 mg, 3.98 mmol, 2 equiv.), oxalic acid (45 mg, 0.50 mmol, 25 mol%) and water (71.7 μ L, 3.98 mmol, 2 equiv.) were added and the reaction was stirred at 78 °C for 16 hours. Sat. NaHCO₃ solution_(aq) was added and the mixture was allowed to warm to room temperature. Ethyl acetate was added and the phases were separated. The aqueous

phase was extracted with ethyl acetate (3x). The combined organic phases were dried over sodium sulfate, filtered, and the solvent was removed under reduced pressure. The residue was purified by column chromatography (CH:EA 80:20) yielding the β -hydroxyketone **24** (375 mg, 1.26 mmol, 63%) as a yellow oil.

TLC: $R_f = 0.36$ (CH:EA 70:30) [KMnO₄]; **[α]**²⁰_D = -12.0 (c = 1.0, DCM); ¹H NMR (400 MHz, CDCI₃): δ [ppm] = 5.85 (ddd, J = 17.2, 10.5, 5.5 Hz, 1H), 5.48 – 5.42 (m, 1H), 5.29 (dt, J = 17.2, 1.5 Hz, 1H), 5.13 (dt, J = 10.5, 1.4 Hz, 1H), 4.60 – 4.50 (m, 1H), 4.22 (ddd, J = 6.4, 1.6, 0.8 Hz, 2H), 3.11 (s, 2H), 2.69 – 2.65 (m, 2H), 1.65 (d, J = 1.2 Hz, 3H), 0.90 (s, 9H), 0.07 (s, 6H); ¹³C NMR (101 MHz, CDCI₃): δ [ppm] = 209.4, 139.1, 130.4, 130.0, 115.2, 68.8, 60.2, 54.7, 48.0, 26.1, 18.5, 16.9, -5.0; IR (ATR): $\tilde{\nu}$ [cm⁻¹] = 3450, 3009, 2954, 2928, 2886, 1710, 1252, 1060, 922, 832, 774; HRMS (ESI): [m/z] 321.1858 (calc'd for C₁₆H₃₀NaO₃Si: 321.1856 [M+Na]⁺).


(3S,5S,E)-9-((tert-butyldimethylsilyl)oxy)-7-methylnona-1,7-diene-3,5-diol (26)



β-hydroxyketone **24** (281 mg, 913 µmol, 1 equiv.) was dissolved in dry methanol/THF (9 mL, 0.1M, 1/4) and cooled to 78 °C. Diethylmethoxyborane (273 µL, 1.10 mmol, 4M in THF, 1.2 equiv.) was then added and then the solution was stirred for 20 min at -78 °C. Sodium borohydride (38.0 mg, 1.00 mmol, 1.1 equiv.) was added and the reaction was stirred for an additional two hours at -78 °C. The reaction was stopped by the addition of sodium hydroxide solution_(aq) (6 mL, 2M) and hydrogen peroxide solution_(aq) (3 mL, 35%) and stirred for 45 minutes at room temperature. After addition of water and ethyl acetate, the phases were separated. The aqueous phase was extracted with ethyl acetate (2x) and the combined organic phases were washed with sat. NaCl solution_(aq), dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. After purification by column chromatography (CH:EA 60:40), the residue obtained afforded the *syn*-diol **26** (272 mg, 905 µmol, 99%, *d.r.* >99:1) as a faint yellow oil.

TLC: $R_f = 0.36$ (CH:EA 50:50) [CAM]; $[\alpha]^{20}{}_{D} = +5.1$ (c = 1.0, DCM); ¹H NMR (600 MHz, CDCl₃): δ [ppm] = 5.87 (ddd, J = 17.1, 10.4, 5.9 Hz, 1H), 5.44 – 5.38 (m, 1H), 5.26 (dt, J = 17.2, 1.4 Hz, 1H), 5.10 (dt, J = 10.4, 1.4 Hz, 1H), 4.42 – 4.33 (m, 1H), 4.23 – 4.18 (m, 2H), 4.02 – 3.96 (m, 1H), 2.92 (s, 2H), 2.20 – 2.14 (m, 2H), 1.70 – 1.56 (m, 5H), 0.90 (s, 9H), 0.07 (s, 6H); ¹³C NMR (151 MHz, CDCl₃): δ [ppm] = 140.8, 133.3, 128.7, 114.5, 73.5, 69.7, 60.1, 48.4, 43.1, 26.1, 18.5, 16.7, -5.0; IR (ATR): $\tilde{\nu}$ [cm⁻¹] = 3365, 3009, 2952, 2929, 2885, 1252, 1065, 832, 773; HRMS (ESI): [m/z] 323.2024 (calc'd for C₁₆H₃₂NaO₃Si: 323.2013 [M+Na]⁺).


(*9S*,*11S*,*E*)-9-((*tert*-butyldimethylsilyl)oxy)-2,2,3,3,7,13,13,14,14-nonamethyl-11-vinyl-4,12dioxa-3,13-disilapentadec-6-ene (**27**)



syn-Diol **26** (263 mg, 831 μmol, 1 equiv.) was placed in dry DMF (1.67 mL, 0.5M). Imidazole (271 mg, 3.99 mmol, 4.8 equiv.) was added and the mixture cooled 0 °C before TBS chloride (313 mg, 2.08 mmol, 2.5 equiv.) was added and the reaction was stirred for two hours at room temperature. Sat. NaHCO₃ solution_(aq) and ethyl acetate were added and the phases were separated. The aqueous phase was extracted with ethyl acetate (3x). The combined organic phases were washed with sat. NaCl solution_(aq), dried over sodium sulfate, filtered, and the solvent was removed under reduced pressure. Purification of the residue by column chromatography (CH:EA 100:0 98:2) afforded product **27** (395 mg, 747 μmol, 90%) as a colorless to light yellow oil.

TLC: $R_f = 0.73$ (CH:EA 90:10) [KMnO₄]; ¹**H NMR** (400 MHz, CDCl₃): δ [ppm] = 5.78 (ddd, J = 17.0, 10.3, 6.5 Hz, 1H), 5.32 (t, J = 5.8 Hz, 1H), 5.14 (dt, J = 17.2, 1.3 Hz, 1H), 5.03 (d, J = 10.4 Hz, 1H), 4.22 (q, J = 6.6 Hz, 1H), 4.17 (d, J = 6.2 Hz, 2H), 3.85 (p, J = 6.3 Hz, 1H), 2.17 (d, J = 6.3 Hz, 2H), 1.70 – 1.57 (m, 5H), 0.90 – 0.87 (m, 27H), 0.07 – 0.02 (m, 18H); ¹³**C NMR** (101 MHz, CDCl₃): δ [ppm] = 141.7, 133.9, 127.8, 114.2, 71.5, 68.2, 60.3, 48.0, 45.9, 26.2, 26.1 (2C), 18.6, 18.4, 18.2, 17.2, -4.0, -4.1, -4.3, -4.6, -4.9 (2C); **IR** (ATR): $\tilde{\nu}$ [cm⁻¹] = 2954, 2922, 2893, 2856, 1471, 1251, 831, 771; **HRMS** (ESI): [m/z] 551.3747 (calc'd for C₂₈H₆₀NaO₃Si₃: 551.3742 [M+Na]⁺).


tert-butyl(((*E*)-4-((*4S*,*6S*)-2,2-dimethyl-6-vinyl-1,3-dioxan-4-yl)-3-methylbut-2-en-1-yl)oxy)dimethylsilane (**28**)



syn-Diol **26** (2.35 g, 7.82 mmol, 1 equiv.) was dissolved in 2,2-dimethoxypropane (24.5 mL, 195 mmol, 25 equiv.) and PPTS (200 mg, 782 µmol, 10 mol%) was added. The reaction mixture was placed on the rotary evaporator at 330 mbar and 45 °C for two hours. The solution was diluted with dichloromethane and washed with sat. NaHCO₃ solution_(aq). The aqueous phase was extracted with dichloromethane (3x) and the combined organic phases were dried with sodium sulfate, filtered and the solvent was removed under reduced pressure. The product **28** (2.62 g, 7.68 mmol, 98%) was obtained with sufficient purity as a colorless oil after aqueous workup.


TLC: $R_f = 0.64$ (CH:EA 50:50) [KMnO₄]; **[α]**²⁰_D = -12.6 (c = 1.0, DCM); ¹H NMR (600 MHz, CDCl₃): δ [ppm] = 5.82 (ddd, J = 17.3, 10.5, 5.8 Hz, 1H), 5.36 (tq, J = 6.3, 1.2 Hz, 1H), 5.24 (dt, J = 17.3, 1.4 Hz, 1H), 5.11 (dt, J = 10.5, 1.3 Hz, 1H), 4.40 – 4.29 (m, 1H), 4.20 (d, J = 6.3 Hz, 2H), 4.08 – 3.96 (m, 1H), 2.27 (dd, J = 13.4, 6.6 Hz, 1H), 2.07 (dd, J = 13.9, 6.5 Hz, 1H), 1.65 (d, J = 0.9 Hz, 3H), 1.56 – 1.52 (m, 1H), 1.47 (s, 3H), 1.43 – 1.41 (m, 3H), 1.29 – 1.20 (m, 1H), 0.90 (s, 9H), 0.07 (s, 6H); ¹³C NMR (151 MHz, CDCl₃): δ [ppm] = 139.0, 133.1, 127.4, 115.4, 98.8, 70.5, 67.6, 60.3, 46.4, 36.7, 30.4, 26.2, 19.9, 18.6, 17.2, -4.9, -4.9; **IR** (ATR): $\tilde{\nu}$ [cm⁻¹] = 3081, 2991, 2930, 2857, 1472, 1463, 1442, 1408, 1378, 1253, 1200, 1169, 1142, 1101, 1074, 1004, 987, 970, 919, 832, 813, 773, 664, 633, 587, 520, 453; **HRMS** (ESI): [m/z] 363.2334 (calc'd for C₁₉H₃₆NaO₃Si: 363.2326 [M+Na]⁺).

(45,65)-6-((E)-4-((*tert*-butyldimethylsilyl)oxy)-2-methylbut-2-en-1-yl)-2,2-dimethyl-1,3dioxane-4-carbaldehyde¹² (**30**)



Alkene 28 (2.60 g, 7.63 mmol, 1 equiv.) was placed in dry THF (15.3 mL, 0.5m) and bis(pinacolato)diboron (3.88 g, 15.3 mmol, 2 equiv.), cesium carbonate (746 mg, 2.29 mmol, 30 mol%) and methanol (5.26 mL, 130 mmol, 17 equiv.) were added successively. The reaction vessel was sealed and stirred at 70 °C for 16 hours. The reaction was then cooled to 0 °C and NaOH solution(aq) (15.3 mL, 45.8 mmol, 3M, 6 equiv.) and hydrogen peroxide solution_(aq) (15.3 mL, 178 mmol, 35%, 23.4 equiv.) were added dropwise. The reaction was warmed to room temperature and stirred for four hours before being cooled again to 0 °C and very carefully stopped with sat. Na₂S₂O₃ solution_(aq). It was diluted with water and ethyl acetate and the phases were separated. The aqueous phase was extracted with ethyl acetate (3x) and the combined organic phases were extracted with 40 °C water until no or very little pinacol could be detected via TLC control. The organic phase was then washed with NaCl solution_(aq), dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The crude product 29 obtained was dissolved in a THF:water mixture (54 mL, 0.14m, 1:1) and sodium periodate (3.53 g, 16.3 mmol, 2.2 equiv.) was added. The reaction was stirred at room temperature for ten minutes before being stopped by the addition of water and ethyl acetate. The phases were separated and the aqueous phase was extracted with ethyl acetate (3x). The combined organic phases were washed with sat. NaCl solution(aq), dried over sodium sulfate, filtered, and the solvent was removed under reduced pressure. After purification by column chromatography (CH:EA 80:20), the residue obtained afforded the aldehyde 30 (2.23 g, 6.50 mmol, 85% over two steps) as a colorless oil.


TLC: $R_f = 0.21$ (CH:EA 80:20) [KMnO₄]; **[α]**²⁰_D = -33.5 (c = 1.0, DCM); ¹H NMR (400 MHz, CDCl₃): δ [ppm] = 9.49 (s, 1H), 5.30 (t, J = 5.9 Hz, 1H), 4.48 (dd, J = 12.1, 2.9 Hz, 1H), 4.21 – 4.07 (m, 3H), 2.15 (dd, J = 13.8, 6.9 Hz, 1H), 2.06 (dd, J = 13.7, 6.0 Hz, 1H), 1.66 (dt, J = 12.9, 2.7 Hz, 1H), 1.62 (s, 3H), 1.44 (s, 3H), 1.34 (s, 3H), 1.20 – 1.06 (m, 1H), 0.86 (s, 9H), 0.03 (s, 6H); ¹³C NMR (101 MHz, CDCl₃): δ [ppm] = 201.3, 132.7, 126.7, 98.5, 73.4, 66.3, 59.4, 45.4, 30.3, 29.6, 25.8, 19.5, 17.9, 16.5, -5.1, -5.1; **IR** (ATR): $\tilde{\nu}$ [cm⁻¹] = 2993, 2954, 2929, 2885, 2856, 1738, 1472, 1463, 1442, 1381, 1252, 1201, 1164, 1110, 1076, 1053, 1006, 976, 949, 832, 814, 774, 664, 572, 521, 458; **HRMS** (ESI): [m/z] 365.2123 (calc'd for C₁₈H₃₄NaO₄Si: 365.2119 [M+Na]⁺). ((*4S*,*6S*)-6-((*E*)-4-((*tert*-butyldimethylsilyl)oxy)-2-methylbut-2-en-1-yl)-2,2-dimethyl-1,3dioxan-4-yl)methanol (**31**)



Aldehyde **30** (2.23g, 6.50 mmol, 1 equiv.) was dissolved in dry dichloromethane (65 mL, 0.1M) and cooled to -78 °C. To this solution, DIBAL-H (7.05 mL, 8.46 mmol, 1.2M in toluene, 1.3 equiv.) was added over ten minutes and the reaction solution was then stirred at -78 °C for an additional 60 minutes. The reaction was stopped by the addition of total K/Na tartrate solution_(aq) (40 mL, 4.5 mL/mmol DIBAL-H) and allowed to warm to room temperature. Glycerol (2 mL, 0.2 mL/mmol DIBAL-H) was added and the emulsion was vigorously stirred for four hours. The phases were separated and the aqueous phase was extracted with dichloromethane (3x). The combined organic phases were washed with sat. NaCl solution_(aq), dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. After purification by column chromatography (CH:EA 70:30), the residue obtained afforded product **31** (2.06 g, 5.98 mmol, 92%) as a colorless oil.

TLC: R_f = 0.25 (CH:EA 80:20) [KMnO₄]; [α]²⁰_D = +1.5 (c = 1.0, DCM); ¹H NMR (600 MHz, *d*₆-DMSO): δ [ppm] = 5.30 – 5.26 (m, 1H), 4.58 (t, *J* = 5.7 Hz, 1H), 4.14 (dt, *J* = 8.9, 4.8 Hz, 2H), 4.05 – 3.98 (m, 1H), 3.84 (dtd, *J* = 11.5, 5.3, 2.5 Hz, 1H), 3.34 (dt, *J* = 11.1, 5.6 Hz, 1H), 3.24 (dt, *J* = 11.0, 5.4 Hz, 1H), 2.12 (dd, *J* = 13.7, 6.9 Hz, 1H), 2.02 (dd, *J* = 13.7, 5.7 Hz, 1H), 1.61 (s, 3H), 1.46 (dt, *J* = 12.8, 2.5 Hz, 1H), 1.38 (s, 3H), 1.25 (s, 3H), 1.02 – 0.93 (m, 1H), 0.86 (s, 9H), 0.03 (s, 6H); ¹³C NMR (151 MHz, *d*₆-DMSO): δ [ppm] = 133.1, 126.4, 97.8, 69.8, 66.7, 64.8, 59.4, 45.8, 33.1, 30.0, 25.8, 19.7, 17.9, 16.5, -5.1, -5.1; IR (ATR): $\tilde{\nu}$ [cm⁻¹] = 3410, 2990, 2952, 2929, 2884, 2857, 1463, 1436, 1379, 1253, 1200, 1164, 1076, 1052, 1006, 971, 940, 833, 814, 774, 733, 664, 570, 525; HRMS (ESI): [m/z] 367.2261 (calc'd for C₁₈H₃₆NaO₄Si: 367.2275 [M+Na]⁺).

tert-butyl(((*E*)-4-((*4S*,*6S*)-6-(((4-methoxybenzyl)oxy)methyl)-2,2-dimethyl-1,3-dioxan-4-yl)-3methylbut-2-en-1-yl)oxy)dimethylsilane (**32**)




Sodium hydride (287 mg, 7.17 mmol, 60% dispersion in mineral oil, 1.2 equiv.) was placed in dry DMF (12 mL) and cooled to 0°C. Then primary alcohol **31** (2.06 g, 5.98 mmol, 1 equiv.) dissolved in DMF (8.0 mL) was added and the solution was stirred for 30 min at this temperature. PMB chloride (1.00 mL, 7.17 mmol, 1.2 equiv.) and TBAI (441 mg, 1.20 mmol, 20 mol%) were added, stirred for one hour at 0 °C, and the solution was warmed to room temperature and stirred for 18 hours. Sat. NH₄Cl solution_(aq) was added and diluted with ethyl acetate. The phases were separated and the aqueous phase was extracted with ethyl acetate (3x). The combined organic phases were washed with sat. NaCl solution_(aq), dried over sodium sulfate, filtered, and the solvent was removed under reduced pressure. The residue

was purified by column chromatography (CH:EA 90:10) and product **32** (2.75 g, 5.86 mmol, 98%) was obtained as a colorless oil.

TLC: R_f = 0.08 (CH:EA 95:5) [KMnO₄]; **[α]**²⁰_D = -6.0 (c = 1.0, DCM); ¹**H** NMR (600 MHz, *d*₆-DMSO): δ [ppm] = 7.23 (d, J = 8.7 Hz, 2H), 6.89 (d, J = 8.7 Hz, 2H), 5.30 – 5.22 (m, 1H), 4.39 (d, J = 3.1 Hz, 2H), 4.13 (d, J = 6.3 Hz, 2H), 4.08 – 3.99 (m, 2H), 3.74 (s, 3H), 3.35 (dd, J = 10.1, 5.8 Hz, 1H), 3.27 (dd, J = 10.1, 4.5 Hz, 1H), 2.12 (dd, J = 13.7, 6.8 Hz, 1H), 2.01 (dd, J = 14.1, 6.2 Hz, 1H), 1.60 (s, 3H), 1.44 (dt, J = 12.8, 2.4 Hz, 1H), 1.38 (s, 3H), 1.25 (s, 3H), 1.02 (q, J = 11.7 Hz, 1H), 0.85 (s, 9H), 0.02 (s, 6H); ¹³C NMR (151 MHz, *d*₆-DMSO): δ [ppm] = 158.7, 133.0, 130.2, 129.2, 126.5, 113.6, 97.9, 72.8, 71.9, 67.9, 66.5, 59.4, 55.0, 45.7, 33.1, 29.9, 25.8, 19.6, 17.9, 16.5, -5.1, -5.1; IR (ATR): $\tilde{\nu}$ [cm⁻¹] = 3032, 2992, 2930, 2856, 1613, 1587, 1513, 1463, 1442, 1378, 1362, 1301, 1246, 1199, 1169, 1103, 1036, 1005, 940, 907, 832, 774, 664, 637, 584, 519; HRMS (ESI): [m/z] 487.2858 (calc'd for C₂₆H₄₄NaO₅Si: 487.2850 [M+Na]⁺).

(9S,11S,E)-9-((tert-butyldimethylsilyl)oxy)-11-(((4-methoxybenzyl)oxy)methyl)-


2,2,3,3,7,13,13,14,14-nonamethyl-4,12-dioxa-3,13-disilapentadec-6-ene (33)



Acetonide **32** (2.75 g, 5.92 mmol, 1 equiv.) was placed in dry methanol (118 mL, 0.05M) and PPTS (379 mg, 1.48 mmol, 25 mol%) was added at room temperature. The reaction was stirred at room temperature for four hours. Subsequently, the solvent was removed under reduced pressure and the residue obtained was taken up in DMF (59.2 mL, 0.1M). Imidazole (4.03 g, 59.2 mmol, 10 equiv.) and TBS chloride (5.35 g, 35.5 mmol, 6 equiv.) were added to the reaction at 0 °C and the reaction was stirred at room temperature for 16 h before being stopped by the addition of water and ethyl acetate. The phases were separated and the aqueous phase was extracted with ethyl acetate (3x). The combined organic phases were washed with sat. NaCl solution_(aq), dried over sodium sulfate, filtered, and the solvent was removed under reduced pressure. After purification by column chromatography (CH:EA 98:2), the residue obtained afforded the triply TBS-protected product **33** (3.42 g, 5.08 mmol, 86% over two steps) as a colorless oil.

TLC: $R_f = 0.45$ (CH:EA 95:5) [KMnO₄]; $[\alpha]^{20}_{D} = +0.6$ (c = 1.0, DCM); ¹H NMR (600 MHz, CDCl₃): δ [ppm] = 7.24 (d, J = 8.5 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 5.32 (t, J = 5.9 Hz, 1H), 4.48 – 4.39 (m, 2H), 4.20 – 4.15 (m, 2H), 3.96 – 3.88 (m, 2H), 3.80 (s, 3H), 3.36 (d, J = 5.0 Hz, 2H), 2.14 (d, J = 6.2 Hz, 2H), 1.74 – 1.68 (m, 1H), 1.61 (s, 3H), 1.59 – 1.55 (m, 1H), 0.90 (s, 9H), 0.88 (s, 9H), 0.86 (s, 9H), 0.06 – 0.04 (m, 12H), 0.00 (2x s, 6H); ¹³C NMR (101 MHz, CDCl₃): δ [ppm] = 159.2, 133.9, 130.8, 129.3, 127.8, 113.8, 74.9, 73.1, 69.4, 68.2, 60.3, 55.4, 48.0, 42.7, 26.2, 26.1, 26.1, 18.6, 18.3, 18.2, 17.3, -4.0, -4.2, -4.3, -4.5, -4.9; IR (ATR): $\tilde{\nu}$ [cm⁻¹] = 2953, 2928, 2887, 2855, 1613, 1513, 1471, 1463, 1442, 1407, 1386, 1361, 1302, 1248, 1173, 1083, 1039, 1005, 938, 831, 808, 772, 664, 574, 513; HRMS (ESI): [m/z] 675.4255 (calc'd for C₃₅H₆₈NaO₅Si₃: 675.4267 [M+Na]⁺).


(2S,4S,E)-2,4,8-tris((tert-butyldimethylsilyl)oxy)-6-methyloct-6-en-1-ol (34)



PMB-protected alcohol **33** (400 mg, 612 μ mol, 1 equiv.) was placed in a dichloromethane:pH7phosphate buffer mixture (12 mL, 0.05m, 1:1) and DDQ (208 mg, 919 μ mol, 1.5 equiv.) was added at 0 °C. The reaction was stirred at 0 °C for 90 min before being stopped by the addition of sat NaHCO₃ solution_(aq) and dichloromethane. The phases were separated and the aqueous phase was extracted with dichloromethane (3x). The combined organic phases were washed with water, dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue obtained was purified by column chromatography (CH:EA 95:5 90:10) to afford the primary alcohol **34** (210 mg, 394 μ mol, 64%) as a colorless oil.

TLC: $R_f = 0.25$ (CH:EA 90:10) [KMnO₄]; **[α]**²⁰_D = +13.4 (c = 1.0, DCM); ¹H NMR (600 MHz, CDCI₃): δ [ppm] = 5.34 (t, J = 5.8 Hz, 1H), 4.17 (d, J = 6.2 Hz, 2H), 3.94 (dq, J = 9.3, 4.7 Hz, 1H), 3.92 – 3.87 (m, 1H), 3.57 (dd, J = 11.2, 4.6 Hz, 1H), 3.46 (dd, J = 11.2, 4.8 Hz, 1H), 2.25 (dd, J = 13.3, 5.7 Hz, 1H), 2.15 (dd, J = 13.3, 7.4 Hz, 1H), 1.71 (ddd, J = 13.8, 8.6, 4.0 Hz, 1H), 1.65 – 1.60 (m, 4H), 0.90 – 0.88 (m, 27H), 0.09 – 0.05 (m, 18H); ¹³C NMR (151 MHz, CDCI₃): δ [ppm] = 133.4, 128.1, 70.1, 68.4, 66.3, 60.2, 48.0, 41.5, 26.2, 26.0 (2C), 18.6, 18.2, 18.2, 17.0, -4.1, -4.3, -4.4 (2C), -5.0 (2C); IR (ATR): $\tilde{\nu}$ [cm⁻¹] = 3459, 2953, 2929, 2886, 2857, 1472, 1463, 1387, 1361, 1252, 1076, 1004, 938, 898, 831, 808, 772, 664, 569, 498; HRMS (ESI): [m/z] 555.3694 (calc'd for C₂₇H₆₀NaO₄Si₃: 555.3692 [M+Na]⁺).

(2S,4S,E)-2,4,8-tris((tert-butyldimethylsilyl)oxy)-6-methyloct-6-enal (7)



Primary alcohol **34** (593 mg, 1.11 mmol, 1 equiv.) was dissolved in DMSO (7.42 mL, 0.15M) and IBX (519 mg, 1.67 mmol, 90% purity, 1.5 equiv.) was added at room temperature. The reaction was stirred at room temperature for 16 hours, the resulting solid was filtered off and washed with plenty of dichloromethane. The filtrate was washed with sat. NaHCO₃ solution_(aq) and the aqueous phase was extracted with dichloromethane (3x). The combined organic phases were dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue obtained was purified by column chromatography (CH:EA 95:5) to afford aldehyde **7** (467 mg, 879 μmol, 79%) as a colorless oil.

TLC: $R_f = 0.65$ (CH:EA 90:10) [KMnO₄]; $[\alpha]^{20}_D = +9.7$ (c = 1.0, DCM); ¹H NMR (400 MHz, CDCI₃): δ [ppm] = 9.60 (d, J = 1.4 Hz, 1H), 5.37 – 5.31 (m, 1H), 4.17 (d, J = 6.2 Hz, 2H), 4.13 – 4.02 (m, 2H), 2.28 (dd, J = 13.2, 5.2 Hz, 1H), 2.11 (dd, J = 13.2, 8.1 Hz, 1H), 1.88 (ddd, J = 14.1, 7.1, 4.1 Hz, 1H), 1.74 (ddd, J = 14.1, 8.0, 4.7 Hz, 1H), 1.64 – 1.60 (m, 3H), 0.92 (s, 9H), 0.90 (s, 9H), 0.87 (s, 9H), 0.09 – 0.05 (m, 18H); ¹³C NMR (101 MHz, CDCI₃): δ [ppm] = 203.9, 133.5, 128.1, 75.0, 66.6, 60.2, 48.1, 40.6, 26.2, 26.1, 25.9, 18.6, 18.5, 18.1, 16.9, -4.1, -4.2, -4.5, -4.7, -4.9, -5.0; IR (ATR): $\tilde{\nu}$ [cm⁻¹] = 2953, 2929, 2887, 2857, 1737, 1472, 1463, 1385, 1362, 1253, 1188, 1079, 1005, 937, 832, 807, 773, 666, 572, 509; HRMS (ESI): [m/z] 553.3538 (calc'd for C₂₇H₅₈NaO₄Si₃: 553.3535 [M+Na]⁺).

methyl (R)-2-((tert-butyldimethylsilyl)oxy)propanoate¹³ (35)



(*R*)-(+)-Methyl lactate (**14**) (2.20 g, 21.1 mmol, 1 equiv.) was dissolved in DMF (16 mL, 1.3M) and imidazole (2.26 g, 31.7 mmol, 1.5 equiv.) and TBS chloride (3.82 g, 25.4 mmol, 1.2 equiv.) were added. The reaction was stirred at room temperature for 30-60 min and then water was added. The mixture was extracted with diethyl ether (3x) and the combined organic phases were washed with sat. NaCl solution_(aq), dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The product **35** (4.80 g, 21.1 mmol, quant.) was obtained without further purification.

¹**H NMR** (600 MHz, CDCl₃): δ [ppm] = 4.33 (q, *J* = 6.8 Hz, 1H), 3.72 (s, 3H), 1.39 (d, *J* = 6.8 Hz, 3H), 0.90 (s, 9H), 0.09 (s, 3H), 0.07 (s, 3H); ¹³**C NMR** (101 MHz, CDCl₃): δ [ppm] = 174.7, 68.6, 52.0, 25.9, 21.5, 18.5, -4.8, -5.1.

The spectroscopic data were identical to those reported in the literature.¹³

(*R*)-2-((*tert*-butyldimethylsilyl)oxy)propanal¹³ (**36**)




The methyl ester **35** (4.80 g, 21.1 mmol, 1 equiv.) was placed in dry dichloromethane (211 mL, 0.1m) and cooled to -78 °C. Subsequently, DIBAL-H (25.3 mL, 25.3 mmol, 1m in dichloromethane, 1.2 equiv.) was slowly added via syringe pump over 30 min and then stirred at -78 °C for one hour. The reaction was terminated with ethyl acetate (30 mL) and sat. K/Na tartrate solution_(aq) (113 mL, 4.5 mL/mmol DIBAL-H) and warmed to room temperature. Glycerol (5 mL, 0.2 mL/mmol DIBAL-H) was subsequently added and the reaction mixture was vigorously stirred for 16 hours. After extraction with dichloromethane (3x), the collected organic phase was washed with sat. NaCl solution_(aq), dried over sodium sulfate, and the solvent was removed under reduced pressure. After vacuum distillation, product **35** (3.44 g, 18.3 mmol, 87%) was obtained as a colorless liquid.

 $[\Box]^{20}{}_{D} = +9.2 (c = 1.0, CHCI_3); Bp = 81-84^{\circ}C (27 mmHg); ^{1}H NMR (600 MHz, CDCI_3): \delta [ppm] = 9.61 (d, J = 1.3 Hz, 1H), 4.09 (qd, J = 6.9, 1.3 Hz, 1H), 1.28 (d, J = 6.9 Hz, 3H), 0.92 (s, 9H), 0.10 (s, 3H), 0.09 (s, 3H); ^{13}C NMR (101 MHz, CDCI_3): \delta [ppm] = 204.3, 74.0, 25.9, 18.7, 18.3, -4.6, -4.6.$

The spectroscopic data were identical to those reported in the literature.¹³


(*R*)-*tert*-butyl((1-(2,2-dimethyl-6-vinyl-1,3-dioxan-4-ylidene)propan-2-yl)oxy)dimethylsilane^{2,3} (**37**)



Diisopropylamine (3.28 mL, 23.4 mmol, 2 equiv.) was placed in dry THF (29 mL) and cooled to 78 °C. *n*Butyllithium (9.35 mL, 23.4 mmol, 2.5M in hexane, 2 equiv.) was added and cooling was removed for 15 min. Cooling was resumed to 78 °C and the (*R*)-polyketide building block **11** (4.00 g, 11.7 mmol, 1 equiv.) dissolved in dry THF (11.7 mL) was added. This caused the solution to turn deep red. After one hour, the aldehyde **36** (6.60 g, 35.1 mmol, 3 equiv.), dissolved in dry THF (17.5 mL), was added and allowed to thaw to room temperature within 90 minutes. The solution became cloudy and orange in the process. Finally, potassium *tert*-butoxide (1.45 g, 12.3 mmol, 1.05 equiv.) was added and stirred for another 60 minutes at room temperature. The solution turned dark orange to brown. The reaction was stopped by adding sat. NH₄Cl solution_(aq) and extracted with dichloromethane (3x). The combined organic phases were washed with sat. NaCl solution_(aq), dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. Purification of the crude product by column chromatography (CH:EA 95:5) afforded product **37** (3.76 g, 11.4 mmol, 98%, *E/Z* 50:50) as a yellow oil.

TLC: $R_f = 0.60$ (CH:EA 80:20) [KMnO₄]; ¹**H NMR** (400 MHz, *d*₆-DMSO): δ [ppm] = 5.89 – 5.75 (m, 1H), 5.30 – 5.22 (m, 1H), 5.17 – 5.09 (m, 1H), 4.89 – 4.49 (m, 2H), 4.42 – 4.29 (m, 1H), 2.15 (dd, *J* = 13.7, 3.1 Hz, 1H), 2.03 – 1.86 (m, 1H), 1.43 – 1.35 (m, 6H), 1.12 (d, *J* = 6.1 Hz, 3H), 0.86 – 0.83 (m, 9H), 0.07 – 0.05 (m, 3H), 0.02 – -0.02 (m, 3H); **IR** (ATR): $\tilde{\nu}$ [cm⁻¹] = 2957, 2928, 2897, 1681, 1371, 1255, 1204, 1129, 1071, 1001, 935, 830, 773, 678; **HRMS** (ESI): [m/z] 335.2015 (calc'd for C₁₇H₃₂NaO₃Si: 335.2013 [M+Na]⁺).


(2R,6R)-2-((tert-butyldimethylsilyl)oxy)-6-hydroxyoct-7-en-4-one¹¹ (38)



Cerium(III) chloride heptahydrate was dried *in vacuo* at 140 °C for two hours to obtain dry cerium(III) chloride before starting the reaction. Acetonide **36** (2.00 g, 6.40 mmol, 1 equiv.) was placed in dry THF (32 mL, 0.2M) and cooled to -78 °C. Cerium(III) chloride (3.16 g, 12.8 mmol, 2 equiv.), oxalic acid (144 mg, 1.60 mmol, 25 mol%), and water (230 μ L, 12.8 mmol, 2 equiv.) were added successively and the reaction was stirred for 16 h at -78 °C. The reaction was stopped by the addition of sat. NaHCO₃ solution(aq) at -78 °C and warmed up to room temperature. Extraction was carried out with ethyl acetate (3x) and the combined organic phases were dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue obtained, after purification by column chromatography (CH:EA 80:20), afforded the β-hydroxyketone **38** (1.31 g, 4.81 mmol, 75%) as a yellow oil.

TLC: $R_f = 0.60$ (CH:EA 80:20) [KMnO₄]; $[\alpha]^{20}_D = -1.4$ (c = 1.0, DCM); ¹H NMR (400 MHz, CDCI₃): δ [ppm] = 5.84 (ddd, J = 17.2, 10.5, 5.5 Hz, 1H), 5.27 (dt, J = 17.2, 1.5 Hz, 1H), 5.11 (dt, J = 10.5, 1.4 Hz, 1H), 4.58 – 4.52 (m, 1H), 4.35 – 4.26 (m, 1H), 2.73 – 2.58 (m, 3H), 2.46 (dd, J = 15.1, 5.1 Hz, 1H), 1.17 (d, J = 6.1 Hz, 3H), 0.86 (s, 9H), 0.06 (s, 3H), 0.04 (s, 3H); ¹³C NMR (151 MHz, CDCI₃): δ [ppm] = 210.2, 139.2, 115.1, 68.7, 65.5, 53.3, 50.5, 25.9, 24.1, 18.1, -4.4, -4.8; IR (ATR): $\tilde{\nu}$ [cm⁻¹] = 3420, 2954, 2928,2856, 1707, 1374, 1253, 1129, 985, 831, 774; HRMS (ESI): [m/z] 295.1696 (calc'd for C₁₄H₂₈NaO₃Si: 295.1700 [M+Na]⁺).


(3R,5R,7R)-7-((tert-butyldimethylsilyl)oxy)-5-hydroxyoct-1-en-3-yl acetate (39)



The reaction was carried out in the absence of light due to the instability of samarium(II) iodide. The β -hydroxyketone **38** (2.20 g, 7.59 mmol, 1 equiv.) was placed in dry THF (15 mL, 0.5M) and cooled to - 50 °C. Acetaldehyde (1.50 mL, 26.6 mmol, 3.5 equiv.) and samarium(II) iodide (56.9 mL, 5.69 mmol, 0.1M in THF, 75 mol%) were added. The deep blue solution was stirred at 50 °C for ten minutes and the reaction decolorized. It was then stirred at 20 °C for an additional 16 hours. The reaction was stopped by the addition of sat. NaHCO₃ solution_(aq) and extracted with ethyl acetate (3x). The combined organic phases were washed with sat. NaCl solution_(aq), dried over sodium sulfate, filtered, and the solvent was removed under reduced pressure. After purification by column chromatography (CH:EA 90:10), the residue obtained afforded the reduction product **39** (2.31 g, 7.31 mmol, 96%, *d.r.* >99:1).

TLC: $R_f = 0.45$ (CH:EA 80:20) [KMnO₄]; **[α]**²⁵_D = -0.6 (c = 1.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ [ppm] = 5.84 (ddd, *J* = 17.1, 10.6, 6.0 Hz, 1H), 5.56 – 5.43 (m, 1H), 5.26 (dt, *J* = 17.3, 1.2 Hz, 1H), 5.15 (dt, *J* = 10.6, 1.1 Hz, 1H), 4.22 – 4.11 (m, 1H), 3.91 – 3.78 (m, 1H), 3.31 (d, *J* = 2.8 Hz, 1H), 2.09 (s, 3H), 1.72 – 1.57 (m, 3H), 1.47 – 1.42 (m, 1H), 1.18 (d, *J* = 6.2 Hz, 3H), 0.88 (s, 9H), 0.07 (s, 3H), 0.07 (s, 3H); ¹³C NMR (101 MHz, CDCl₃): δ [ppm] = 171.3, 136.8, 116.3, 72.1, 66.4, 64.0, 45.6, 43.2, 26.0, 23.8, 21.3, 18.1, -4.2, -4.9; **IR** (ATR): $\tilde{\nu}$ [cm⁻¹] = 3516, 2955, 2929, 2856, 1721, 1372, 1257, 1147, 1080, 1058, 1019, 929, 834, 805, 773; **HRMS** (ESI): [m/z] 339.1963 (calc'd for C₁₆H₃₂NaO₄Si: 339.1962 [M+Na]⁺).

(3R,5R,7R)-7-((tert-butyldimethylsilyl)oxy)oct-1-ene-3,5-diol (40)




Method A: Tetramethylammonium triacetoxyborohydride (1.07 g, 3.85 mmol, 5 equiv.) was placed in acetonitrile:acetic acid (8 mL, 5:3) and cooled to -25 °C. Subsequently, β -hydroxyketone **38** (210 mg, 770 µmol, 1 equiv.) dissolved in acetonitrile (0.8 mL) was added and the reaction was stirred at -25 °C for 22 hours. Sat. K/Na tartrate solution_(aq) was added and the reaction was stirred for an additional 45 minutes at room temperature. The mixture was transferred to a separatory funnel and extracted with dichloromethane (3x). The organic phase was washed with sat. NaHCO₃ solution_(aq) and the aqueous phase was extracted again with dichloromethane (3x). The combined organic phases were dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue obtained, after purification by column chromatography (CH:EA 70:30), gave the product **40** (212 mg, 0.75 mmol, 97%, *d.r.* 77:23) as a colorless oil.

Method B: Acetate **39** (2.31 g, 1.42 mmol, 1 equiv.) was dissolved in methanol:water (22 mL, 0.33M, 3:1) and potassium carbonate (2.02 g, 14.6 mmol, 2 equiv.) was added at 0 °C. The reaction was stirred at room temperature for 60 minutes and then water and ethyl acetate were added. The phases were separated and the aqueous phase was extracted with ethyl acetate (3x). The combined organic phases

were washed with sat. NaCl solution_(aq), dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue obtained, after purification by column chromatography (CH:EA 70:30), gave product **39** (1.98 g, 7.22 mmol, 99%) as a colorless oil.

TLC: $R_f = 0.44$ (CH:EA 50:50) [KMnO₄]; **[α]**²⁰_D = -16.1 (c = 1.0, DCM); ¹H NMR (400 MHz, CDCI₃): δ [ppm] = 5.93 (ddd, J = 17.2, 10.5, 5.4 Hz, 1H), 5.30 (dt, J = 17.2, 1.6 Hz, 1H), 5.12 (dt, J = 10.5, 1.5 Hz, 1H), 4.50 – 4.43 (m, 1H), 4.40 – 4.32 (m, 1H), 4.29 – 4.18 (m, 1H), 3.93 (s, 1H), 3.06 (s, 1H), 1.81 (ddd, J = 14.2, 10.2, 3.9 Hz, 1H), 1.73 (ddd, J = 14.3, 8.5, 3.4 Hz, 1H), 1.60 (ddd, J = 14.3, 7.8, 3.2 Hz, 1H), 1.46 (ddd, J = 14.3, 4.7, 2.1 Hz, 1H), 1.25 (d, J = 6.3 Hz, 3H), 0.89 (s, 9H), 0.10 (s, 3H), 0.09 (s, 3H); ¹³C NMR (101 MHz, CDCI₃): δ [ppm] = 141.1, 114.2, 70.5, 68.0, 66.1, 43.8, 43.0, 25.9, 22.7, 18.1, -4.4, -4.9; IR (ATR): $\tilde{\nu}$ [cm⁻¹] = 3374, 2954, 2929, 2856, 1409, 1375, 1253, 1088, 1066, 986, 920, 832, 806, 773; HRMS (ESI): [m/z] 297.1847 (calc'd for C₁₄H₃₀NaO₃Si: 297.1856 [M+Na]⁺).


tert-butyl(((*R*)-1-((*4R*,*6R*)-2-(4-methoxyphenyl)-6-vinyl-1,3-dioxan-4-yl)propan-2-yl)oxy)dimethylsilane (**41**)



To a solution of the *anti*-diol **40** (362 mg, 1.32 mmol, 1 equiv.) in dry dichloromethane (6.6 mL, 0.2M) were added 1-(dimethoxymethyl)-4-methoxybenzene (343 μ L, 1.98 mmol, 1.5 equiv.) and PPTS (24 mg, 92 μ mol, 7 mol%) and the reaction was stirred for 16 hours at room temperature. The reaction was stopped by the addition of sat. NaHCO₃ solution_(aq) and extracted with dichloromethane (3x). The combined organic phases were dried over sodium sulfate, filtered, and the solvent was removed under reduced pressure. Column chromatographic purification (CH:EA 93:7 \rightarrow 90:10) gave the protected product **41** (571 mg, 1.18 mmol, 81% purity, 89%, *d.r.* 8:2) as a yellowish oil.


TLC: $R_f = 0.49$ (CH:EA 80:20) [UV, KMnO₄]; **¹H NMR** (400 MHz, CDCl₃): δ [ppm] = 7.42 (dq, J = 9.6, 2.4 Hz, 2H), 6.93 – 6.85 (m, 2H), 6.16 – 5.84 (m, 1H), 5.76 (s, 1H), 5.39 (ddd, J = 11.0, 2.2, 1.2 Hz, 1H), 5.37 – 5.27 (m, 1H), 4.79 (dt, J = 4.4, 2.4 Hz, 1H), 4.24 – 3.95 (m, 2H), 3.80 (s, 3H), 2.13 – 1.99 (m, 1H), 1.73 – 1.58 (m, 2H), 1.48 (ddd, J = 14.2, 9.9, 2.3 Hz, 1H), 1.17 (dd, J = 32.0, 6.1 Hz, 3H), 0.89 (s, 9H), 0.04 (s, 6H); **IR** (ATR): $\tilde{\nu}$ [cm⁻¹] = 3076, 2953, 2928, 2855, 1615, 1516, 1373, 1246, 1170, 1115, 1034, 922, 823, 773; **HRMS** (ESI): [m/z] 415.2271 (calc'd for C₂₂H₃₆NaO₄Si: 415.2275 [M+Na]⁺).

(3R,5R,7R)-7-((tert-butyldimethylsilyl)oxy)-5-((4-methoxybenzyl)oxy)oct-1-en-3-ol (42)



Acetal **41** (2.51 g, 6.39 mmol, 1 equiv.) was placed in dry dichloromethane (71 mL, 0.09M) and cooled to 0 °C. To this solution was added DIBAL-H (28.5 mL, 28.5 mmol, 1M in DCM, 4.45 equiv.) at 0 °C. The reaction was stirred at 0 °C for ten minutes and then carefully stopped with sat. NH₄Cl solution_(aq). Sat. K/Na tartrate solution_(aq) (143 mL, 5 mL/mmol DIBAL H) was added and stirred for 30 minutes at room temperature. The resulting phases were separated and the aqueous phase was extracted with ethyl acetate (3x). The combined organic phases were dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue obtained, after purification by column chromatography (CH:EA 85:15 \rightarrow 80:20), gave product **42** (2.35 g, 5.96 mmol, 93%) as a colorless oil.


TLC: R_f = 0.44 (CH:EA 50:50) [UV, KMnO₄]; **[α]**²⁰_D = -7.9 (c = 1.0, DCM); ¹**H NMR** (400 MHz, CDCl₃): δ [ppm] = 7.27 (d, J = 2.1 Hz, 2H), 6.90 – 6.86 (m, 2H), 5.87 (ddd, J = 17.2, 10.5, 5.4 Hz, 1H), 5.27 (dt, J = 17.2, 1.6 Hz, 1H), 5.10 (dt, J = 10.5, 1.5 Hz, 1H), 4.52 (d, J = 10.7 Hz, 1H), 4.45 (d, J = 10.7 Hz, 1H), 4.42 – 4.39 (m, 1H), 4.04 – 3.94 (m, 1H), 3.90 – 3.82 (m, 1H), 3.80 (s, 3H), 3.00 (d, J = 3.7 Hz, 1H), 1.91 – 1.79 (m, 2H), 1.74 – 1.58 (m, 2H), 1.16 (d, J = 6.1 Hz, 3H), 0.89 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H); ¹³**C NMR** (101 MHz, CDCl₃): δ [ppm] = 159.5, 141.1, 130.5, 129.6, 114.2, 114.1, 74.8, 71.0, 70.2, 66.1, 55.5, 44.8, 40.4, 26.1, 24.6, 18.2, -3.8, -4.4; **IR** (ATR): $\tilde{\nu}$ [cm⁻¹] = 3463, 3076, 3033, 2997, 2953, 2929, 2855, 1612, 1513, 1463, 1246, 1173, 1035, 918, 822, 772; **HRMS** (ESI): [m/z] 417.2431 (calc'd for C₂₂H₃₈NaO4Si: 417.2432 [M+Na]⁺). (*5R*,*7S*,*9R*)-7-((4-methoxybenzyl)oxy)-2,2,3,3,5,11,11,12,12-nonamethyl-9-vinyl-4,10-dioxa-3,11-disilatridecane (**43**)



The secondary alcohol **42** (997 mg, 2.48 mmol, 1 equiv.) was dissolved in dry DMF (5 mL, 0.5M) and imidazole (505 mg, 7.43 mmol, 3 equiv.) was added. The reaction was cooled to 0 °C and TBS chloride (560 mg, 3.71 mmol, 1.5 equiv.) was added. The mixture was stirred at room temperature for 16 h and then terminated by the addition of sat. NaHCO₃ solution_(aq). Extraction was carried out with ethyl acetate (4x) and the combined organic phases were washed with sat. NaCl solution_(aq), dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. After purification by column chromatography (CH:EA 95:5), the residue obtained afforded the product **43** (1.20 g, 2.36 mmol, 95%) as a colorless oil.

TLC: R_f = 0.69 (CH:EA 80:20) [UV, KMnO₄]; **[α]**²⁰_D = -8.9 (c = 1.0, DCM); ¹**H NMR** (400 MHz, CDCl₃): δ [ppm] = 7.28 – 7.25 (m, 2H), 6.90 – 6.84 (m, 2H), 5.82 (ddd, J = 17.1, 10.3, 6.7 Hz, 1H), 5.20 – 5.11 (m, 1H), 5.07 – 5.00 (m, 1H), 4.47 – 4.39 (m, 2H), 4.27 (q, J = 6.6 Hz, 1H), 4.06 – 3.96 (m, 1H), 3.80 (s, 3H), 3.70 (p, J = 6.8, 6.1 Hz, 1H), 1.83 – 1.57 (m, 4H), 1.15 (d, J = 6.1 Hz, 3H), 0.90 (s, 9H), 0.89 (s, 9H), 0.10 – 0.00 (m, 12H); ¹³**C NMR** (101 MHz, CDCl₃): δ [ppm] = 159.2, 142.0, 131.4, 129.2, 114.2, 114.0, 73.3, 71.5, 70.3, 65.9, 55.5, 45.6, 44.0, 26.1 (2C), 24.5, 18.3, 18.2, -3.8, -3.9, -4.4, -4.5; **IR** (ATR): $\tilde{\nu}$ [cm⁻¹] = 3075, 2997, 2954, 2928, 2894, 2856, 1513, 1462, 1247, 1064, 1038, 922, 832, 806, 772, **HRMS** (ESI): [m/z] 531.3298 (calc'd for C₂₈H₅₂NaO₄Si₂: 531.3296 [M+Na]⁺).

(3S,5S,7R)-3,7-bis((tert-butyldimethylsilyl)oxy)-5-((4-methoxybenzyl)oxy)octan-1-ol (44)




Terminal alkene **43** (1.11 g, 2.18 mmol, 1 equiv.) was placed in dry THF (22 mL, 0.1 μ) and cooled to 0 °C. 9-BBN (13.1 mL, 6.54 mmol, 0.5 μ in THF, 3 equiv.) was added and the solution was stirred at 0 °C for 15 minutes before stirring at room temperature for another 15 hours. To stop the reaction, the solution was again cooled to 0 °C and NaOH solution_(aq) (2.18 mL, 6.54 mmol, 3 μ , 3 equiv.) and hydrogen peroxide solution_(aq) (2.19 mL, 25.5 mmol, 35%, 11.7 equiv.) were added. The mixture was stirred for 15 minutes at 0 °C and four hours at room temperature. Water was added and the mixture was extracted with diethyl ether (3x). The combined organic phases were washed with sat. NaCl solution_(aq), dried over

sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue after purification by column chromatography (CH:EA 85:15) afforded the primary alcohol **44** (1.12 g, 2.10 mmol, 97%) as a colorless oil.

TLC: R_{*f*} = 0.21 (CH:EA 80:20) [UV, KMnO₄]; **[α]**²⁰_D = -22.8 (c = 1.0, DCM); ¹H NMR (400 MHz, CDCl₃): δ [ppm] = 7.26 – 7.23 (m, 2H), 6.87 (d, J = 8.7 Hz, 2H), 4.46 (d, J = 10.8 Hz, 1H), 4.41 (d, J = 10.8 Hz, 1H), 4.09 – 3.97 (m, 2H), 3.91 – 3.81 (m, 1H), 3.80 (s, 3H), 3.77 – 3.68 (m, 1H), 3.66 – 3.54 (m, 1H), 2.37 (s, 1H), 1.99 – 1.83 (m, 2H), 1.71 – 1.55 (m, 4H), 1.15 (d, J = 6.1 Hz, 3H), 0.90 (s, 9H), 0.89 (s, 9H), 0.11 (s, 3H), 0.09 (s, 3H), 0.07 (s, 3H), 0.05 (s, 3H); ¹³C NMR (101 MHz, CDCl₃): δ [ppm] = 159.3, 131.0, 129.3, 114.0, 73.6, 70.2, 69.5, 65.7, 60.2, 55.5, 45.4, 41.9, 38.3, 26.1, 26.0, 24.6, 18.2, 18.1, -3.8, -4.2, -4.4, -4.5; **IR** (ATR): $\tilde{\nu}$ [cm⁻¹] = 3442, 2952, 2928, 2855, 1613, 1513, 1462, 1247, 1108, 1036, 1004, 832, 806, 772; **HRMS** (ESI): [m/z] 549.3402 (calc'd for C₂₈H₅₄NaO₅Si₂: 549.3402 [M+Na]⁺).


5-(((*3R*,*5S*,*7R*)-3,7-bis((*tert*-butyldimethylsilyl)oxy)-5-((4-methoxybenzyl)oxy)octyl)thio)-1phenyl-*1H*-tetrazole (**45**)



Primary alcohol **44** (1.10 g, 2.07 mmol, 1 equiv.) was placed in dry THF (21 mL, 0.1M) and cooled to 0 °C. To this mixture was added 1-phenyl-*1H*-tetrazole-5-thiol (737 mg, 4.13 mmol, 2 equiv.), triphenylphosphine (813 mg, 3.10 mmol, 1.5 equiv.), and diisopropyl azodicarboxylate (779 μ L, 3.72 mmol, 1.8 equiv.) and the reaction was stirred at 0 °C for four hours. The solvent was removed under reduced pressure, and the residue obtained, after purification by column chromatography (CH:EA 95:5 \rightarrow 90:10), afforded product **45** (1.33 g, 1.94 mmol, 94%) as a colorless oil.

TLC: R_f = 0.42 (CH:EA 80:20) [UV, KMnO₄]; **[α]**²⁰_D = -9.8 (c = 1.0, DCM); ¹**H** NMR (400 MHz, CDCl₃): δ [ppm] = 7.60 – 7.50 (m, 5H), 7.26 – 7.21 (m, 2H), 6.88 – 6.82 (m, 2H), 4.43 (s, 2H), 4.06 – 3.93 (m, 2H), 3.79 (s, 3H), 3.68 – 3.59 (m, 1H), 3.53 – 3.38 (m, 2H), 2.09 – 1.92 (m, 2H), 1.89 – 1.80 (m, 1H), 1.74 – 1.54 (m, 3H), 1.15 (d, J = 6.1 Hz, 3H), 0.89 (s, 9H), 0.86 (s, 9H), 0.08 – 0.04 (m, 12H); ¹³**C** NMR (101 MHz, CDCl₃): δ [ppm] = 159.2, 154.5, 134.0, 131.1, 130.2, 129.9, 129.2, 124.0, 114.0, 73.4, 70.2, 68.6, 65.8, 55.4, 45.5, 42.5, 36.8, 29.2, 26.1, 26.1, 24.5, 18.2, 18.2, -3.9, -4.1 (2C), -4.4; **IR** (ATR): $\tilde{\nu}$ [cm⁻¹] = 2999, 2952, 2928, 2855, 1610, 1513, 1500, 1385, 1247, 1108, 1071, 1037, 1005, 833, 755, 693; **HRMS** (ESI): [m/z] 709.3612 (calc'd for C₃₅H₅₈NaO₄SSi₂: 709.3610 [M+Na]⁺). 5-(((3R,5S,7R)-3,7-bis((tert-butyldimethylsilyl)oxy)-5-((4-methoxybenzyl)oxy)octyl)sulfonyl)-


1-phenyl-1H-tetrazole (8)



Sulfide **45** (1.30 g, 1.89 mmol, 1 equiv.) was placed in dry ethanol (9.5 mL, 0.2 μ) and cooled to 0 °C. To this mixture was added (NH₄)₆Mo₇O₂₄·4H₂O (468 mg, 378 μ mol, 20 mol%) dissolved in hydrogen peroxide solution_(aq) (1.62 mL, 18.9 mmol, 35%, 10 equiv.). The reaction mixture was stirred for three hours at room temperature. Water and dichloromethane were then added to the reaction and the resulting phases were separated. The aqueous phase was extracted with dichloromethane (3x). The combined organic phases were washed with sat. NaCl solution_(aq), dried over sodium sulfate, filtered, and the solvent was removed under reduced pressure. Column chromatographic purification (CH:EA 90:10) of the residue afforded sulfone **8** (1.23 g, 1.71 mmol, 90%) as a colorless oil.

TLC: $R_f = 0.42$ (CH:EA 80:20) [UV, KMnO₄]; $[\alpha]^{20}{}_{D} = -2.0$ (c = 1.0, DCM); ¹H NMR (400 MHz, CDCl₃): δ [ppm] = 7.71 – 7.66 (m, 2H), 7.61 (td, J = 5.7, 2.7 Hz, 3H), 7.24 (d, J = 8.7 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 4.47 (d, J = 10.8 Hz, 1H), 4.39 (d, J = 10.8 Hz, 1H), 4.10 – 3.97 (m, 2H), 3.79 (s, 5H), 3.66 – 3.58 (m, 1H), 2.28 – 2.15 (m, 1H), 2.11 – 2.00 (m, 1H), 1.80 – 1.70 (m, 2H), 1.69 – 1.54 (m, 2H), 1.16 (d, J = 6.1 Hz, 3H), 0.90 (s, 9H), 0.88 (s, 9H), 0.07 (m, 12H); ¹³C NMR (101 MHz, CDCl₃): δ [ppm] = 159.3, 153.7, 133.3, 131.5, 130.9, 129.8, 129.2, 125.2, 114.0, 73.3, 70.2, 67.5, 65.9, 55.4, 52.3, 45.3, 42.6, 29.6, 26.1, 26.0, 24.4, 18.2, 18.1, -3.9, -4.2, -4.3, -4.4; IR (ATR): $\tilde{\nu}$ [cm⁻¹] = 3069, 2953, 2928, 2896, 1611, 1513, 1462, 1342, 1258, 1072, 1036, 833, 807, 773, 757, 687, 530; HRMS (ESI): [m/z] 741.3509 (calc'd for C₃₅H₅₈N₄NaO₆SSi₂: 741.3508 [M+Na]⁺).

5-hydroxy-2,2-diphenyl-4H-benzo[d][1,3]dioxin-4-one¹⁴ (16)




2,6-Dihydroxybenzoic acid (**15**) (3.00 g, 18.9 mmol, 1 equiv.) was placed in dry dimethoxyethane (15.7 mL, 1.2M). Benzophenone (4.47 g, 24.6 mmol, 1.3 equiv.) and DMAP (115 mg, 945 µmol, 5 mol%) were added and the reaction was cooled to 0 °C. Thionyl chloride (1.79 mL, 24.6 mmol, 1.3 equiv.) was added dropwise and the reaction was stirred at 0 °C for an additional 60 min before warming to room temperature and stirring for another 18 hours. The reaction was stopped by adding sat. NaHCO₃ solution_(aq) and diethyl ether. The phases were separated and the aqueous phase was extracted with diethyl ether (4x). The combined organic phases were dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue was purified by column chromatography (CH:EA

95:5). Recrystallization of the combined fractions after removal of the solvent from pentane:diethyl ether (170 mL, 9:1) afforded product **16** (1.83 g, 5.75 mmol, 30%) as a white solid.

TLC: R_f = 0.19 (CH:EA 95:5) [UV]; **¹H NMR** (400 MHz, CDCl₃): δ [ppm] = 10.16 (s, 1H), 7.63 – 7.59 (m, 4H), 7.45 – 7.36 (m, 7H), 6.68 (dd, *J* = 8.2, 0.9 Hz, 1H), 6.59 (dd, *J* = 8.5, 0.9 Hz, 1H); ¹³**C NMR** (101 MHz, CDCl₃): δ [ppm] = 165.7, 161.6, 156.2, 139.3, 138.2, 129.6, 128.8, 126.6, 111.3, 107.7, 107.6, 101.1.

The spectroscopic data were identical to those reported in the literature.¹⁴

4-oxo-2,2-diphenyl-4H-benzo[d][1,3]dioxin-5-yl acetate (9)




Phenol **16** (5.07 g, 15.9 mmol, 1 equiv.) was dissolved in dry dichloromethane (159 mL, 0.1M). Pyridine (6.44 mL, 79.6 mmol, 5 equiv.) and DMAP (195 mg, 1.59 mmol, 10 mol%) were added and the reaction mixture was cooled to 0 °C. Acetic anhydride (2.71 mL, 28.7 mmol, 1.8 equiv.) was added and the reaction was stirred at 0 °C for 30 min and at room temperature for another 90 min. The reaction was stopped by the addition of sat. NaHCO₃ solution_(aq) and the two phases were separated. The aqueous phase was extracted with dichloromethane (3x). The combined organic phases were dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue obtained was purified by column chromatography (CH:EA 8:2) furnishing product **9** (5.10 g, 14.2 mmol, 89%) as a white solid.

TLC: $R_f = 0.29$ (CH:EA 8:2) [UV, KMnO₄]; **¹H NMR** (400 MHz, CDCl₃): δ [ppm] = 7.58 – 7.53 (m, 4H), 7.50 (t, J = 8.2 Hz, 1H), 7.39 – 7.30 (m, 6H), 7.06 (dd, J = 8.4, 1.0 Hz, 1H), 6.71 (dd, J = 8.1, 1.0 Hz, 1H), 2.34 (s, 3H); ¹³**C NMR** (101 MHz, CDCl₃): δ [ppm] = 169.0, 158.1, 157.5, 151.8, 139.3, 136.3, 129.4, 128.6, 126.7, 118.0, 115.5, 108.9, 107.0, 21.0; **IR** (ATR): $\tilde{\nu}$ [cm⁻¹] = 3112, 3094, 3066, 2972, 1737, 1617, 1472, 1449, 1336, 1318, 1269, 1193, 1099, 1059, 960, 907, 877, 820, 758; **HRMS** (ESI): [m/z] 383.0889 (calc'd for C₂₂H₁₆NaO₅: 383.0890 [M+Na]⁺).

2.3 Fragment assembly

(*6E,9S,11S,12E,15S,17S,19R*)-9,11,15-tris((*tert*-butyldimethylsilyl)oxy)-17-((4methoxybenzyl)oxy)-2,2,3,3,7,19,21,21,22,22-decamethyl-4,20-dioxa-3,21-disilatricosa-6,12diene (**46**)




Sulfone **8** (955 mg, 1.12 mmol, 93% purity, 1.15 equiv.) was placed in the reaction vessel before the start of the reaction and dried azeotropically with benzene under reduced pressure. Dry DME (24 mL) was added and the reaction mixture was cooled to -78 °C. To this solution was added KHMDS (2.58 mL, 1.29 mmol, 0.5m in toluene, 1.2 equiv.) and the resulting yellow solution was stirred at -78 °C for 30 min. Aldehyde **7** (570 mg, 1.07 mmol, 1 equiv.) dissolved in DME (10.7 mL) was then added via syringe pump at -78 °C for half an hour. After the addition was completed, the reaction solution was stirred for an additional 2.5 hours at -78 °C before the reaction was warmed to room temperature and stopped by the addition of sat. NH₄Cl solution_(aq). Ethyl acetate was added and the phases separated. The aqueous phase was extracted with ethyl acetate (3x) and the combined organic phases were washed with sat. NaCl solution_(aq), dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. After purification by column chromatography (CH:EA 97:3), the residue obtained afforded product **46** (961 mg, 910 µmol, 85%, *E/Z* >99:1) as a colorless oil.

TLC: R_{*f*} = 0.45 (CH:EA 95:5) [KMnO₄]; [**α**]²⁰_D = -4.6 (c = 1.0, DCM); ¹**H NMR** (600 MHz, CDCl₃): δ [ppm] = 7.24 (d, J = 8.7 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 5.58 (dt, J = 15.4, 7.1 Hz, 1H), 5.42 (dd, J = 15.4, 7.0 Hz, 1H), 5.36 – 5.30 (m, 1H), 4.42 (s, 2H), 4.20 – 4.14 (m, 3H), 4.03 – 3.98 (m, 1H), 3.95 – 3.91 (m, 1H), 3.85 (p, J = 6.1 Hz, 1H), 3.79 (s, 3H), 3.71 – 3.65 (m, 1H), 2.30 – 2.09 (m, 4H), 1.80 – 1.73 (m, 1H), 1.72 – 1.64 (m, 2H), 1.62 – 1.49 (m, 6H), 1.14 (d, J = 6.1 Hz, 3H), 0.90 (s, 9H), 0.89 (s, 18H), 0.88 (s, 9H), 0.87 (s, 9H), 0.07 – 0.05 (m, 18H), 0.04 (s, 3H), 0.03 – -0.00 (m, 9H); ¹³C NMR (101 MHz, CDCl₃): δ [ppm] = 159.0, 136.2, 133.8, 131.3, 128.9, 127.6, 126.2, 113.7, 73.3, 71.0, 69.9, 69.0, 68.1, 65.7, 60.2, 55.3, 47.7, 46.3, 45.3, 42.2, 40.5, 26.0, 26.0 (2C), 26.0, 25.9, 24.3, 18.4, 18.2, 18.1 (2C), 18.0, 17.1, -3.9, -4.0 (2C), -4.2, -4.3, -4.5, -4.6, -5.1 (2C); **IR** (ATR): $\tilde{\nu}$ [cm⁻¹] = 2953, 2928, 2886, 2856, 1614, 1514, 1472, 1463, 1361, 1301, 1249, 1172, 1068, 1005, 974, 938, 832, 807, 771, 664, 570, 509; **HRMS** (ESI): [m/z] 1045.6988 (calc'd for C₅₅H₁₁₀NaO₇Si₅: 1045.6990 [M+Na]⁺).

(5R,7S,9S,11E,13S,15S,17E)-9,13,15-tris((tert-butyldimethylsilyl)oxy)-

2,2,3,3,5,17,21,21,22,22-decamethyl-4,20-dioxa-3,21-disilatricosa-11,17-dien-7-ol (47)




PMB-protected secondary alcohol **46** (50 mg, 47 mmol, 1 equiv.) was placed in a dichloromethane:pH7-phosphate buffer mixture (1.0 mL, 0.05m, 1:1) and cooled to 0 °C. To this solution was added DDQ (16

mg, 71 μ mol, 1.5 equiv.) and the reaction was stirred at 0 °C for two hours. Then, sat. NaHCO₃ solution_(aq) and dichloromethane were added and the phases were separated. The aqueous phase was extracted with dichloromethane (3x) and the combined organic phases were washed with water, dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue obtained was purified by column chromatography (CH:EA 95:5) to give product **47** (39 mg, 43 μ mol, 90%) as a faint yellowish oil.

TLC: $R_f = 0.30$ (CH:EA 95:5) [KMnO₄]; $[\alpha]^{20}_{D} = -1.2$ (c = 1.0, DCM); ¹H NMR (600 MHz, CDCl₃): δ [ppm] = 5.52 (dt, J = 15.5, 7.0 Hz, 1H), 5.41 (dd, J = 15.5, 7.0 Hz, 1H), 5.32 (t, J = 6.2 Hz, 1H), 4.21 – 4.11 (m, 5H), 4.06 – 4.01 (m, 1H), 3.84 (p, J = 6.2 Hz, 1H), 3.48 (s, 1H), 2.32 – 2.11 (m, 4H), 1.70 – 1.64 (m, 1H), 1.62 – 1.50 (m, 6H), 1.46 – 1.36 (m, 2H), 1.18 (d, J = 6.2 Hz, 3H), 0.92 – 0.86 (m, 45H), 0.12 – 0.01 (m, 30H); ¹³C NMR (151 MHz, CDCl₃): δ [ppm] = 136.4, 133.9, 127.8, 126.4, 71.1, 69.8, 68.2, 66.9, 64.4, 60.3, 47.9, 46.4, 46.0, 43.4, 40.4, 26.2, 26.1, 26.1, 26.1, 26.0, 23.5, 18.6, 18.3, 18.2 (2C), 18.1, 17.2, - 3.8, -4.0, -4.2, -4.3, -4.5, -4.7, -4.8, -4.9 (2C); IR (ATR): $\tilde{\nu}$ [cm⁻¹] = 3522, 2954, 2929, 2887, 2856, 1472, 1463, 1408, 1379, 1361, 1252, 1068, 1004, 972, 938, 832, 808, 772, 730, 664, 570.; HRMS (ESI): [m/z] 925.6414 (calc'd for C₄₇H₁₀₂NaO₆Si₅: 925.6415 [M+Na]⁺).

(5R,7S,9S,11E,13S,15S,17E)-9,13,15-tris((tert-butyldimethylsilyl)oxy)-2,2,3,3,5,17,21,21,22,22-decamethyl-4,20-dioxa-3,21-disilatricosa-11,17-dien-7-yl 2-acetoxy-

6-hydroxybenzoate¹⁴ (49)




Secondary alcohol **47** (285 mg, 306 µmol, 1 equiv.) and aryl acetate **9** (276 mg, 765 µmol, 2.5 equiv.) were dissolved in dry and degassed dichloromethane (1.53 mL, 0.2 μ) and distributed to five NMR tubes under argon atmosphere (~0.3 mL solution per tube). The reaction tubes were placed in a UV reactor and irradiated with light ($\lambda_{max} = 310$ nm) for five hours. The irradiation was briefly interrupted every 60 minutes and the NMR tubes were shaken for 20 seconds. After the reaction time was completed, the tubes were diluted with dichloromethane and all reaction solutions were worked up together. The organic phase was washed with sat. NaCl solution_(aq) and the aqueous phase was extracted with dichloromethane (5x). The combined organic phases were dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue obtained was purified by column chromatography (CH:EA 97:3). The resulting by-product in the form of benzophenone could not be readily separated and was successfully removed only in the next reaction step. Product **49** (337 mg, 219 µmol, 72%, 70% purity (benzophenone as impurity)) could thus be obtained as a colorless oil.

TLC: $R_f = 0.30$ (CH:EA 95:5) [KMnO₄]; $[\alpha]^{20}_{D} = -6.1$ (c = 1.0, DCM); ¹H NMR (600 MHz, CDCl₃): δ [ppm] = 11.48 (s, 1H), 7.40 (t, J = 8.2 Hz, 1H), 6.90 (dd, J = 8.5, 1.1 Hz, 1H), 6.53 (dd, J = 7.9, 1.1 Hz, 1H),

5.57 (dt, J = 14.5, 7.0 Hz, 1H), 5.43 (td, J = 15.4, 14.6, 7.0 Hz, 2H), 5.32 (t, J = 6.2 Hz, 1H), 4.20 – 4.13 (m, 3H), 3.92 – 3.82 (m, 3H), 2.32 – 2.22 (m, 4H), 2.20 – 2.08 (m, 3H), 1.84 – 1.65 (m, 5H), 1.60 (s, 3H), 1.55 – 1.51 (m, 1H), 1.15 (d, J = 6.1 Hz, 3H), 0.90 – 0.85 (m, 45H), 0.07 – -0.00 (m, 27H), -0.02 (s, 3H); 1³**C NMR** (151 MHz, CDCl₃): δ [ppm] = 169.2, 169.0, 163.6, 150.8, 136.9, 134.9, 133.9, 127.8, 125.6, 116.2, 114.4, 107.6, 72.5, 71.1, 68.7, 68.2, 65.2, 60.3, 47.8, 46.5, 45.8, 42.6, 40.8, 26.2, 26.1, 26.1, 26.1, 24.6, 21.4, 18.6, 18.3, 18.2, 18.2, 18.1, 17.2, -3.8, -3.9, -4.0, -4.1, -4.2, -4.5, -4.6, -4.7, -4.9; **IR** (ATR): $\tilde{\nu}$ [cm⁻¹] = 3466, 2954, 2929, 2887, 2856, 1773, 1665, 1617, 1472, 1461, 1362, 1319, 1300, 1250, 1199, 1063, 1032, 1005, 974, 938, 906, 832, 809, 772, 733, 705, 664, 605, 574, 484, 445; **HRMS** (ESI): [m/z] 1098.7128 (calc'd for C₅₆H₁₁₂NO₁₀Si₅: 1098.7127 [M+NH₄]⁺).

(5R,7S,9S,11E,13S,15S,17E)-9,13,15-tris((tert-butyldimethylsilyl)oxy)-

2,2,3,3,5,17,21,21,22,22-decamethyl-4,20-dioxa-3,21-disilatricosa-11,17-dien-7-yl 2-acetoxy-6-(((trifluoromethyl)sulfonyl)oxy)benzoate (**49a**)




Phenol **49** (335 mg, 217 μ mol, 70% purity, 1 equiv.) was placed in dry dichloromethane (2.2 mL, 0.1 μ) and cooled to 0 °C. Pyridine (87.7 μ L, 1.08 mmol, 5 equiv.) and trifluoromethanesulfonic anhydride (72.8 μ L, 434 μ mol, 2 equiv.) were added and the reaction was stirred at 0 °C for 30 minutes before stirring at room temperature for an additional two hours. The reaction was stopped by the addition of sat. NaHCO₃ solution_(aq) and extracted with dichloromethane (4x). The combined organic phases were dried over sodium sulfate, filtered, and the solvent was removed under reduced pressure. The residue obtained, after purification by column chromatography (CH:EA 95:5), afforded product **49a** (239 mg, 197 μ mol, 91%) as a colorless oil.

TLC: $R_f = 0.12$ (CH:EA 95:5) [KMnO₄]; [α]²⁰_D = -3.4 (c = 1.0, DCM); ¹H NMR (600 MHz, CDCl₃): δ [ppm] = 7.54 (t, J = 8.4 Hz, 1H), 7.24 (d, J = 8.4 Hz, 1H), 7.20 (dd, J = 8.3, 0.9 Hz, 1H), 5.55 (dt, J = 15.4, 7.0 Hz, 1H), 5.42 (dd, J = 15.4, 7.0 Hz, 1H), 5.32 (t, J = 5.7 Hz, 1H), 5.20 – 5.15 (m, 1H), 4.21 – 4.10 (m, 3H), 3.94 – 3.88 (m, 1H), 3.88 – 3.80 (m, 2H), 2.29 (s, 3H), 2.28 – 2.14 (m, 3H), 2.10 (dd, J = 13.3, 7.0 Hz, 1H), 1.94 – 1.86 (m, 2H), 1.83 – 1.72 (m, 2H), 1.71 – 1.63 (m, 1H), 1.60 (s, 3H), 1.57 – 1.48 (m, 1H), 1.16 (d, J = 6.1 Hz, 3H), 0.91 – 0.88 (m, 27H), 0.86 (s, 18H), 0.07 – 0.06 (m, 9H), 0.05 (s, 6H), 0.04 (s, 3H), 0.03 – 0.01 (m, 6H), -0.00 (s, 3H), -0.02 (s, 3H); ¹³C NMR (151 MHz, CDCl₃): δ [ppm] = 168.7, 161.1, 150.8, 147.8, 136.6, 134.0, 132.1, 127.7, 125.8, 124.2, 121.1, 119.78 (q, J = 320.6 Hz), 119.5, 74.1, 71.1, 68.8, 68.2, 65.7, 60.3, 47.7, 46.6, 44.9, 41.9, 40.8, 26.2, 26.1, 26.1, 26.1, 26.1, 24.3, 21.0, 18.6, 18.3, 18.2, 18.1, 18.1, 17.2, -3.8, -4.1, -4.2 (2C), -4.2, -4.4, -4.5, -4.6, -4.9 (2C; ¹⁹F NMR (376 MHz, CDCl₃): δ [ppm] = -73.2; IR (ATR): $\tilde{\nu}$ [cm⁻¹] = 2954, 2929, 2887, 2857, 1783, 1731, 1613, 1472, 1461, 1430, 1362, 1252, 1216, 1186, 1141, 1065, 1015, 988, 938, 888, 832, 807, 772, 742, 705, 664, 603, 575, 532, 507; HRMS (ESI): [m/z] 1235.6141 (calc'd for C₅₇H₁₀₇F₃NaO₁₂SSi₅: 1235.6174 [M+Na]⁺).

2,2,3,3,5,17,21,21,22,22-decamethyl-4,20-dioxa-3,21-disilatricosa-11,17-dien-7-yl


(methoxymethoxy)-6-(((trifluoromethyl)sulfonyl)oxy)benzoate (50)



The aryl acetate **49a** (215 mg, 172 µmol, 1 equiv.) was dissolved in a mixture of dry methanol:THF (3.4 mL, 0.05M, 1:1) and potassium carbonate (11.9 mg, 85.9 µmol, 0.5 equiv.) was added at room temperature. The reaction was stirred at room temperature for one hour and then water and dichloromethane were added. The phases were separated and the aqueous phase was extracted with dichloromethane (5x). The combined organic phases were washed with sat. NaCl solution_(aq), dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The crude product was dissolved in dry dichloromethane (3.4 mL, 0.05M) and cooled to 0 °C. To this solution was added DIPEA (151 µL, 859 µmol, 5 equiv.) and MOMCI (27.5 µL, 344 µmol, 2 equiv.). The reaction was stirred for 60 min at 0 °C and 16 h at room temperature before being stopped by the addition of water. The phases were separated and the aqueous phase was extracted with dichloromethane (5x). The combined organic phases were separated and the addition of water. The phases were separated and the aqueous phase was extracted with dichloromethane (5x) and MOMCI (27.5 µL, 344 µmol, 2 equiv.). The reaction was stirred for 60 min at 0 °C and 16 h at room temperature before being stopped by the addition of water. The phases were separated and the aqueous phase was extracted with dichloromethane (5x). The combined organic phases were dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue obtained was purified by column chromatography (CH:EA 95:5). Product **50** (208 mg, 163 µmol, 95%) was obtained as a colorless oil.

TLC: $R_f = 0.14$ (CH:EA 95:5) [KMnO4]; [α]²⁰_D = +4.3 (c = 1.0, DCM); ¹H NMR (600 MHz, C₆D₆): δ [ppm] = 6.84 – 6.79 (m, 1H), 6.73 (d, *J* = 8.0 Hz, 1H), 6.69 (d, *J* = 8.4 Hz, 1H), 5.85 (dt, *J* = 14.6, 7.0 Hz, 1H), 5.69 – 5.56 (m, 3H), 4.78 (q, *J* = 7.0 Hz, 2H), 4.38 (q, *J* = 6.6 Hz, 1H), 4.26 (d, *J* = 6.2 Hz, 2H), 4.19 – 4.12 (m, 2H), 4.08 (p, *J* = 6.1 Hz, 1H), 3.17 (s, 3H), 2.42 (h, *J* = 7.6 Hz, 2H), 2.30 (dd, *J* = 13.3, 5.3 Hz, 1H), 2.26 – 2.16 (m, 2H), 2.12 (ddd, *J* = 14.0, 7.3, 4.2 Hz, 1H), 2.06 – 1.93 (m, 3H), 1.81 (dt, *J* = 13.4, 6.2 Hz, 1H), 1.67 (s, 3H), 1.25 (d, *J* = 6.1 Hz, 3H), 1.07 (d, *J* = 5.6 Hz, 18H), 1.04 – 1.00 (m, 27H), 0.30 (s, 3H), 0.26 (s, 3H), 0.19 (s, 3H), 0.18 – 0.14 (m, 12H), 0.14 – 0.10 (m, 9H); ¹³C NMR (151 MHz, C₆D₆): δ [ppm] = 170.0, 162.5, 156.2, 147.3, 137.2, 133.9, 131.4, 126.2, 120.25 (q, *J* = 320.7 Hz), 119.7, 114.8, 114.1, 94.9, 73.4, 71.5, 69.3, 68.7, 66.1, 60.4, 56.2, 48.0, 47.1, 45.7, 42.6, 41.3, 26.3 (2C), 26.3 (2C), 26.2, 24.7, 18.6, 18.4, 18.4 (2C), 18.3, 17.4, -3.5, -3.9 (2C), -4.0, -4.0, -4.1, -4.2, -4.4, -4.9 (2C); **IR** (ATR): $\tilde{\nu}$ [cm⁻¹] = 2955, 2928, 2856, 1730, 1612, 1581, 1462, 1428, 1254, 1216, 1141, 1121, 1070, 1018, 833, 774; **HRMS** (ESI): [m/z] 1237.6322 (calc'd for C₅₇H₁₀₉F₃NaO₁₂SSi₅: 1237.6330 [M+Na]⁺).


(*5R*,*7S*,*9S*,*13S*,*15S*,*E*)-9,13-bis((*tert*-butyldimethylsilyl)oxy)-15-((*E*)-4-hydroxy-2-methylbut-2en-1-yl)-2,2,3,3,5,17,17,18,18-nonamethyl-4,16-dioxa-3,17-disilanonadec-11-en-7-yl 2-(methoxymethoxy)-6-(((trifluoromethyl)sulfonyl)oxy)benzoate¹⁵ (**50a**)



TBS-protected primary alcohol **50** (30.0 mg, 23.4 μ mol, 1 equiv.) was dissolved in a mixture of THF:water (234 μ L, 0.1 μ , 4:1) and sodium periodate (30.4 mg, 140 μ mol, 6 equiv.) was added at room temperature. The reaction was stirred at room temperature for five hours before being stopped by the addition of water and dichloromethane. The phases were separated and the aqueous phase was extracted with dichloromethane (5x). The combined organic phases were dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. After purification by column chromatography (CH:EA 80:20), the residue obtained afforded product **50a** (10.5 mg, 9.53 μ mol, 41% (87% brsm)) and the unreacted starting material **50** (13.0 mg, 10.7 μ mol, 46%) as colorless oils.

TLC: $R_f = 0.22$ (CH:EA 80:20) [KMnO4]; [α]²⁰_D = -1.4 (c = 1.0, DCM); ¹H NMR (400 MHz, C₆D₆): δ [ppm] = 6.81 (dd, J = 8.2, 1.1 Hz, 1H), 6.75 – 6.64 (m, 2H), 5.86 (dt, J = 15.4, 7.0 Hz, 1H), 5.71 – 5.56 (m, 2H), 5.50 – 5.43 (m, 1H), 4.83 – 4.73 (m, 2H), 4.38 (q, J = 6.6 Hz, 1H), 4.21 – 4.04 (m, 3H), 4.00 (d, J = 6.6 Hz, 2H), 3.16 (s, 3H), 2.42 (t, J = 6.1 Hz, 2H), 2.33 – 2.16 (m, 3H), 2.14 – 1.92 (m, 4H), 1.85 – 1.76 (m, 1H), 1.62 (s, 3H), 1.24 (d, J = 6.1 Hz, 3H), 1.07 – 1.05 (m, 18H), 1.02 – 0.99 (m, 18H), 0.29 (s, 3H), 0.26 (s, 3H), 0.18 – 0.15 (m, 12H), 0.14 (s, 3H), 0.11 (s, 3H); ¹³C NMR (151 MHz, C₆D₆): δ [ppm] = 162.6, 156.2, 147.3, 137.2, 135.3, 131.4, 126.2, 119.7, 119.2 (q, J = 321.1 Hz), 114.8, 114.1, 95.0, 73.5, 71.5, 69.4, 68.6, 66.0, 59.4, 56.2, 48.0, 47.0, 45.7, 42.6, 41.2, 30.2, 26.3 (2C), 26.2, 26.2, 24.7, 18.4, 18.4, 18.3, 18.3, 17.2, -3.5, -3.9, -4.0, -4.0, -4.1, -4.2, -4.4; ¹⁹F NMR (376 MHz, C₆D₆): δ [ppm] = -73.6; IR (ATR): \tilde{v} [cm⁻¹] = 3436, 2954, 2928, 2897, 2856, 1736, 1612, 1582, 1462, 1428, 1253, 1216, 1142, 1088, 1068, 1017, 833, 774, 605; HRMS (ESI): [m/z] 1123.5426 (calc'd for C₅₁H₉₅F₃NaO₁₂SSi4: 1123.5466 [M+Na]⁺).


(*5R*,*7S*,*9S*,*13S*,*15S*,*E*)-9,13-bis((*tert*-butyldimethylsilyl)oxy)-2,2,3,3,5,17,17,18,18-nonamethyl-15-((*E*)-2-methyl-4-oxobut-2-en-1-yl)-4,16-dioxa-3,17-disilanonadec-11-en-7-yl 2-(methoxymethoxy)-6-(((trifluoromethyl)sulfonyl)oxy)benzoate (**50b**)



Primary alcohol **50a** (68.0 mg, 61.7 μmol, 1 equiv.) was dissolved in dry dichloromethane (1.23 mL, 0.05M) and manganese(IV) oxide (316 mg, 3.09 mmol, 85% strength, 50 equiv.) was added at room temperature. The reaction was stirred for 16 hours and then filtered over Celite[®]. The filter cake was washed with a large amount of dichloromethane and the filtrate was concentrated under reduced pressure. The obtained aldehyde **50b** (67.9 mg, 61.7 μmol, quant.) was used as crude material for the next reaction without further purification.

TLC: $R_f = 0.43$ (CH:EA 80:20) [UV, KMnO₄]; **1H NMR** (600 MHz, C_6D_6): δ [ppm] = 9.93 (d, J = 7.7 Hz, 1H), 6.81 (dd, J = 8.3, 1.0 Hz, 1H), 6.73 – 6.65 (m, 2H), 6.01 – 5.97 (m, 1H), 5.86 (dt, J = 15.4, 7.0 Hz, 1H), 5.62 (dd, J = 15.3, 7.1 Hz, 2H), 4.81 – 4.75 (m, 2H), 4.27 (q, J = 7.4 Hz, 1H), 4.20 – 4.05 (m, 3H), 3.16 (s, 3H), 2.43 (t, J = 6.1 Hz, 2H), 2.29 – 2.19 (m, 2H), 2.16 – 2.07 (m, 2H), 2.05 – 1.97 (m, 2H), 1.97 – 1.90 (m, 1H), 1.83 (d, J = 1.2 Hz, 3H), 1.71 – 1.65 (m, 1H), 1.24 (d, J = 6.1 Hz, 3H), 1.09 – 1.05 (m, 18H), 1.00 (s, 9H), 0.96 (s, 9H), 0.29 (s, 3H), 0.27 (s, 3H), 0.18 (s, 3H), 0.16 – 0.14 (m, 6H), 0.13 – 0.11 (m, 6H), 0.03 (s, 3H).

(*5R*,*7S*,*9S*,*13S*,*15S*,*E*)-9,13-bis((*tert*-butyldimethylsilyl)oxy)-2,2,3,3,5,17,17,18,18-nonamethyl-15-((*E*)-2-methylpent-2-en-4-yn-1-yl)-4,16-dioxa-3,17-disilanonadec-11-en-7-yl 2-(methoxymethoxy)-6-(((trifluoromethyl)sulfonyl)oxy)benzoate (**51**)



Trimethylsilyldiazomethane (66.3 µL, 133 µmol, 2M in diethyl ether, 1.8 equiv.) was placed in dry THF (736 µL) and cooled to -78 °C. To this solution was added *n*-butyllithium (44.2 µL, 110 µmol, 2.5M in hexane, 1.5 equiv.) and the reaction was stirred at 78 °C for 30 min. Aldehyde **50b** (81.0 mg, 73.7 µmol, 1 equiv.) dissolved in dry THF (736 µL) was then added to this solution. After completed addition, the reaction was stirred at -78 °C for 30 minutes, then at 0 °C for two hours, and finally at room temperature for 60 minutes before the reaction was stopped by the addition of total NH₄Cl solution_(aq). Extraction was carried out with dichloromethane (5x) and the combined organic phases were dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue obtained was purified by column chromatography (CH:EA 95:5 → 90:10). The terminal alkyne **51** (54.2 mg, 49.5 µmol, 67%) was obtained as a colorless oil.


TLC: $R_f = 0.22$ (CH:EA 80:20) [KMnO₄]; [α]²⁰_D = -4.0 (c = 1.0, DCM); ¹H NMR (600 MHz, C_6D_6): δ [ppm] = 6.81 (dd, J = 8.4, 0.7 Hz, 1H), 6.72 (d, J = 8.2 Hz, 1H), 6.67 (t, J = 8.4 Hz, 1H), 5.84 (dt, J = 15.4, 7.1 Hz, 1H), 5.65 – 5.57 (m, 2H), 5.46 – 5.43 (m, 1H), 4.80 – 4.75 (m, 2H), 4.30 (q, J = 7.1 Hz, 1H), 4.20 – 4.10 (m, 2H), 4.10 – 4.03 (m, 1H), 3.16 (s, 3H), 2.83 (d, J = 2.1 Hz, 1H), 2.46 – 2.37 (m, J = 6.2, 5.1 Hz, 2H), 2.27 (dd, J = 13.3, 4.6 Hz, 1H), 2.23 – 2.14 (m, 2H), 2.14 – 2.07 (m, 1H), 2.05 – 1.92 (m, 6H), 1.75 – 1.69 (m, 1H), 1.25 (d, J = 6.1 Hz, 3H), 1.08 – 1.06 (m, 18H), 1.01 – 0.99 (m, 18H), 0.30 (s, 3H), 0.27 (s, 3H), 0.19 (s, 3H), 0.16 – 0.12 (m, 15H); ¹³C NMR (151 MHz, C_6D_6): δ [ppm] = 162.5, 156.2, 150.8, 147.3, 137.1, 131.4, 126.3, 119.7, 119.2 (q, J = 320.5 Hz), 114.8, 114.1, 107.8, 94.9, 81.9, 80.7, 73.4, 71.4, 69.3, 68.3, 66.0, 56.2, 47.2, 46.7, 45.7, 42.6, 41.1, 26.3, 26.3, 26.2, 26.2, 24.7, 20.3, 18.4, 18.4, 18.3, 18.3, -3.5, -3.9, -4.0, -4.1, -4.1, -4.2, -4.2, -4.4; IR (ATR): $\hat{\nu}$ [cm⁻¹] = 3314, 2954, 2929, 2896, 2857, 2099, 1736, 1612, 1582, 1472, 1462, 1428, 1387, 1361, 1253, 1217, 1157, 1142, 1087, 1070, 1019, 976, 938, 889, 834, 774, 725, 664, 604, 509; HRMS (ESI): [m/z] 1117.5350 (calc'd for $C_{52}H_{93}F_3NaO_{11}SSi_4$: 1117.5360 [M+Na]⁺).

(*5R*,*7S*,*9S*,*13S*,*15S*,*E*)-9,13-bis((*tert*-butyldimethylsilyl)oxy)-2,2,3,3,5,17,17,18,18-nonamethyl-15-((*2E*,*4E*,*6E*)-2-methyl-9-(trimethylsilyl)nona-2,4,6-trien-8-yn-1-yl)-4,16-dioxa-3,17-

disilanonadec-11-en-7-yl

2-(methoxymethoxy)-6-

(((trifluoromethyl)sulfonyl)oxy)benzoate^{16,17} (5)



Under argon atmosphere and light exclusion, zirconocene dichloride (44.8 mg, 153 µmol, 4 equiv.) was dissolved in dry THF (383 µL). Super-Hydride[®] solution (153 µL, 153 µmol, 1м in THF, 4 equiv.) was slowly added. The reaction was stirred at room temperature for one hour before adding a solution of alkyne **51** (42 mg, 38 µmol, 1 equiv.) dissolved in dry THF (164 µL). The mixture was stirred for an additional hour at room temperature and then *N*-iodosuccinimide (43.1 mg, 192 µmol, 5 equiv.) was added in one portion. After 15 minutes of reaction time, sat. Na₂S₂O₃ solution_(aq) was added until complete decolorization. The mixture was transferred to a separatory funnel and extracted with dichloromethane (5x). The combined organic phases were dried over sodium sulfate, filtered, and the solvent was removed under reduced pressure. The residue obtained was purified by column chromatography (CH:EA 95:5). The unstable dienyl iodide **52** (22 mg, 18 µmol, 47%) was obtained as an intermediate.

TLC: $R_f = 0.17$ (CH:EA 95:5) [KMnO₄]; **¹H NMR** (600 MHz, C₆D₆): δ [ppm] = 7.27 (dd, J = 14.2, 11.2 Hz, 1H), 6.81 (dd, J = 8.3, 0.8 Hz, 1H), 6.72 (d, J = 7.9 Hz, 1H), 6.68 (t, J = 8.4 Hz, 1H), 5.97 (d, J = 14.2 Hz, 1H), 5.89 – 5.81 (m, 1H), 5.71 (d, J = 11.1 Hz, 1H), 5.66 – 5.59 (m, 2H), 4.81 – 4.74 (m, 2H), 4.35 (q, J = 6.7 Hz, 1H), 4.20 – 4.10 (m, 2H), 4.02 (p, J = 6.2 Hz, 1H), 3.16 (s, 3H), 2.47 – 2.38 (m, 2H), 2.23 – 2.17 (m, 2H), 2.17 – 2.07 (m, 2H), 2.05 – 1.92 (m, 3H), 1.80 – 1.71 (m, 1H), 1.55 – 1.52 (m, 3H), 1.25 (d, J = 6.1 Hz, 3H), 1.08 – 1.05 (m, 18H), 1.01 (s, 9H), 0.99 (s, 9H), 0.30 (s, 3H), 0.27 (s, 3H), 0.20 – 0.13 (m, 15H), 0.06 (s, 3H).

Intermediate **52** was immediately further reacted. Lithium chloride (11.4 mg, 270 µmol, 15 equiv.), Ph₃As (4.4 mg, 14 µmol, 80 mol%), and Pd₂(dba)₃ (1.7 mg, 1.8 µmol, 10 mol%) were placed in a heated 4-mL vial and dry DMF (180 µL) was added. The reaction mixture was stirred at room temperature for five minutes before a solution of the intermediate **52** (22 mg, 18 µmol, 1 equiv.) and stannane **6** (8.2 mg, 20 µmol, 1.1 equiv.) in dry DMF (540 µL) was added. The reaction mixture was stirred for two hours at room temperature and then stirred further at 40 °C for two hours. After purification by column chromatography (CH:EA 95:5), the reaction mixture afforded the protected monomer **5** (8.0 mg, 6.6 µmol, 36% (17% over two steps)) as an orange oil.


TLC: $R_f = 0.17$ (CH:EA 95:5) [KMnO₄]; **[a]**²⁰_D = -7.3 (c = 0.7, DCM); ¹H NMR (600 MHz, C₆D₆): δ [ppm] = 6.81 (d, J = 7.9 Hz, 1H), 6.78 – 6.70 (m, 2H), 6.67 (dd, J = 9.8, 7.0 Hz, 1H), 6.38 (dd, J = 14.6, 11.4 Hz,

1H), 6.01 (dd, J = 14.6, 11.2 Hz, 1H), 5.95 (d, J = 11.2 Hz, 1H), 5.91 – 5.80 (m, 1H), 5.70 – 5.61 (m, 2H), 5.60 (d, J = 15.5 Hz, 1H), 4.78 (q, J = 7.0 Hz, 2H), 4.38 (q, J = 6.6 Hz, 1H), 4.20 – 4.13 (m, 2H), 4.09 (p, J = 6.1 Hz, 1H), 3.16 (s, 3H), 2.47 – 2.38 (m, 2H), 2.35 (dd, J = 13.2, 5.1 Hz, 1H), 2.31 – 2.25 (m, 1H), 2.24 – 2.17 (m, 1H), 2.15 – 2.08 (m, 1H), 2.06 – 1.96 (m, 3H), 1.83 – 1.69 (m, 4H), 1.25 (d, J = 6.1 Hz, 3H), 1.08 – 1.06 (m, 18H), 1.03 – 1.01 (m, 18H), 0.30 (s, 3H), 0.27 (s, 3H), 0.23 (s, 9H), 0.19 – 0.16 (m, 12H), 0.15 (s, 3H), 0.10 (s, 3H); 1³**C** NMR (101 MHz, C₆D₆): δ [ppm] = 162.5, 156.2, 147.3, 143.9, 139.1, 137.1, 134.2, 132.3, 131.4, 130.5, 126.3, 119.7, 119.2 (q, J = 320.7 Hz), 114.9, 114.1, 110.4, 106.2, 97.6, 95.0, 73.4, 71.5, 69.4, 68.7, 66.0, 56.2, 48.7, 47.3, 45.7, 42.6, 41.2, 26.3 (2C), 26.2, 26.2, 24.7, 18.4, 18.4, 18.3, 18.3, 17.9, 0.2, -3.5, -3.9, -4.0, -4.0, -4.1, -4.1, -4.2, -4.4; ¹⁹F NMR (376 MHz, C₆D₆): δ [ppm] = -73.5; **IR** (ATR): $\hat{\nu}$ [cm⁻¹] = 3025, 2955, 2929, 2897, 2856, 2164, 2117, 1737, 1611, 1582, 1472, 1462, 1429, 1375, 1361, 1252, 1217, 1156, 1142, 1070, 1020, 981, 938, 835, 775, 726, 664, 605, 509; **HRMS** (ESI): [m/z] 1241.6089 (calc'd for C₅₉H₁₀₅F₃NaO₁₁Si₅: 1241.6068 [M+Na]⁺).

3. References


- 1 R. Zibuck and J. M. Streiber, J. Org. Chem., 1989, 54, 4717.
- 2 A. Bredenkamp, M. Wegener, S. Hummel, A. P. Häring and S. F. Kirsch, *Chem. Commun.*, 2016, **52**, 1875.
- 3 A. Bredenkamp, Z.-B. Zhu and S. F. Kirsch, *Eur. J. Org. Chem.*, 2016, **2016**, 252.
- 4 L. Ferrié, J. Fenneteau and B. Figadère, Org. Lett., 2018, 20, 3192.
- 5 C. T. Brain, A. Chen, A. Nelson, N. Tanikkul and E. J. Thomas, *Tetrahedron*, 2010, **66**, 6613.
- 6 P. A. Wender, S. M. Sieburth, J. J. Petraitis and S. K. Singh, *Tetrahedron*, 1981, **37**, 3967.
- L. Gao, C. Su, X. Du, R. Wang, S. Chen, Y. Zhou, C. Liu, X. Liu, R. Tian, L. Zhang, K. Xie, S. Chen,
 Q. Guo, L. Guo, Y. Hano, M. Shimazaki, A. Minami, H. Oikawa, N. Huang, K. N. Houk, L. Huang,
 J. Dai and X. Lei, *Nat. Chem.*, 2020, **12**, 620.
- 8 S. D. Burke, A. D. Piscopio, M. E. Kort, M. A. Matulenko, M. H. Parker, D. M. Armistead and K. Shankaran, *J. Org. Chem.*, 1994, **59**, 332.
- 9 V. T. Tran and K. A. Woerpel, J. Org. Chem., 2013, **78**, 6609.
- 10 J. A. Lafontaine, D. P. Provencal, C. Gardelli and J. W. Leahy, J. Org. Chem., 2003, 68, 4215.
- 11 X. Xiao and D. Bai, *Synlett*, 2001, **2001**, 535.
- 12 T. P. Blaisdell, T. C. Caya, L. Zhang, A. Sanz-Marco and J. P. Morken, *J. Am. Chem. Soc.*, 2014, **136**, 9264.
- 13 S. M. Gibson, R. M. Lanigan, L. Benhamou, A. E. Aliev and T. D. Sheppard, *Org. Biomol. Chem.*, 2015, **13**, 9050.
- 14 O. Soltani and J. K. de Brabander, *Angew. Chem. Int. Ed.*, 2005, 44, 1696.
- 15 J. Li and D. Menche, *Synthesis*, 2009, **2009**, 1904.
- 16 P. A. Evans, M.-H. Huang, M. J. Lawler and S. Maroto, *Nat. Chem.*, 2012, 4, 680.
- 17 B. H. Lipshutz, R. Keil and E. L. Ellsworth, *Tetrahedron Lett.*, 1990, **31**, 7257.

4. Spectra




140 130 120 110 100 90 f1 (ppm) -20 210 200 170 160 -10

¹H and ¹³C spectra of compound 24




150 140 130 120 110 100 90 80 70 60 f1 (ppm)





130 120 110 100 90 f1 (ppm) -10 . 200


$^{1}\mathrm{H}$ and $^{13}\mathrm{C}$ spectra of compound 27



























¹H spectrum of compound 37



















220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 f1 (ppm) ¹H spectrum of compound 41














































¹⁹F spectrum of compound 49a








¹H spectrum of compound 50b





¹H spectrum of compound 52



